




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/31, 15/53, 15/54, 15/62, C12P 21/00, A61K 39/095		A1	(11) International Publication Number: WO 95/03413
			(43) International Publication Date: 2 February 1995 (02.02.95)
(21) International Application Number: PCT/US94/08327		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).	
(22) International Filing Date: 22 July 1994 (22.07.94)			
(30) Priority Data: 08/096,182 23 July 1993 (23.07.93) US			
(71) Applicants: THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, NY 10021 (US). NORTH AMERICAN VACCINE, INC. [US/US]; 12103 Indian Creek Court, Beltsville, MD 20705 (US).		Published <i>With international search report.</i>	
(72) Inventors: BLAKE, Milan, S.; Apartment 30P, 504 East 63rd Street, New York, NY 10021 (US). TAI, Joseph, Y.; 1370 Cinnamon Drive, Fort Washington, PA 19034 (US). QI, Huilin, L.; Apartment 5M, 504 East 81st Avenue, New York, NY 10028 (US). LIANG, Shu-Mei; 6627 River Road, Bethesda, MD 20817 (US). HRONOWSKI, Lucjan, J., J.; 9160-F Hitching Post Lane, Laurel, MD 20723 (US). PULLEN, Jeffrey, K.; 6928 Garland Lane, Columbia, MD 21045 (US).			
(74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein & Fox, Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).			

(54) Title: HIGH LEVEL EXPRESSION, PURIFICATION AND REFOLDING OF THE NEISSERIA MENINGITIDIS OUTER MEMBRANE GROUP B PORIN PROTEINS



(57) Abstract

The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in *E. coli* wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2 % of the total protein expressed in *E. coli*, exemplified by the use of the plasmid expression vector porB-pET-17b depicted in the figure. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HIGH LEVEL EXPRESSION, PURIFICATION AND REFOLDING OF THE NEISSERIA MENINGITIDIS OUTER MEMBRANE GROUP B PORIN PROTEINS

Background of the Invention

5 *Field of the Invention*

The present invention is in the field of recombinant genetics, protein expression, and vaccines. The present invention relates, in particular, to a method of expressing in a recombinant host an outer membrane group B porin protein from *Neisseria meningitidis*. The invention also relates to a
10 method of purification and refolding of the recombinant protein.

Background Information

The outer membranes of *Neisseria* species much like other Gram negative bacteria are semi-permeable membranes which allow free flow access and escape of small molecular weight substances to and from the periplasmic space of these bacteria but retard molecules of larger size
15 (Heasley, F.A., *et al.*, "Reconstitution and characterization of the *N. gonorrhoeae* outer membrane permeability barrier," in *Genetics and Immunobiology of Neisseria gonorrhoeae*, Danielsson and Normark, eds., University of Umea, Umea, pp. 12-15 (1980); Douglas, J.T., *et al.*, *FEMS Microbiol. Lett.* 12:305-309 (1981)). One of the mechanisms whereby this is accomplished is the inclusion within these membranes of proteins which have been collectively named porins. These proteins are made up of three
20 identical polypeptide chains (Jones, R.B., *et al.*, *Infect. Immun.* 30:773-780 (1980); McDade, Jr. and Johnston, *J. Bacteriol.* 141:1183-1191 (1980)) and in their native trimer conformation, form water filled, voltage-dependent channels within the outer membrane of the bacteria or other
25 membranes to which they have been introduced (Lynch, E.C., *et al.*, *Biophys. J.* 41:62 (1983); Lynch, E.C., *et al.*, *Biophys. J.* 45:104-107

- 2 -

(1984); Young, J.D.E., *et al.*, *Proc. Natl. Acad. Sci. USA* 80:3831-3835 (1983); Mauro, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:1071-1075 (1988); Young, J.D., *et al.*, *Proc. Natl. Acad. Sci. USA* 83:150-154 (1986)). Because of the relative abundance of these proteins within the outer membrane, these protein antigens have also been used to subgroup both *Neisseria gonorrhoeae* and *Neisseria meningitidis* into several serotypes for epidemiological purposes (Frasch, C.E., *et al.*, *Rev. Infect. Dis.* 7:504-510 (1985); Knapp, J.S., *et al.*, "Overview of epidemiological and clinical applications of auxotype/serovar classification of *Neisseria gonorrhoeae*," *The Pathogenic Neisseriae*, Schoolnik, G.K., ed., American Society for Microbiology, Washington, pp. 6-12 (1985)). To date, many of these proteins from both gonococci and meningococci have been purified (Heckels, J.E., *J. Gen. Microbiol.* 99:333-341 (1977); James and Heckels, *J. Immunol. Meth.* 42:223-228 (1981); Judd, R.C., *Anal. Biochem.* 173:307-316 (1988); Blake and Gotschlich, *Infect. Immun.* 36:277-283 (1982); Wetzler, L.M., *et al.*, *J. Exp. Med.* 168:1883-1897 (1988)), and cloned and sequenced (Gotschlich, E.C., *et al.*, *Proc. Natl. Acad. Sci. USA* 84:8135-8139 (1987); McGuinness, B., *et al.*, *J. Exp. Med.* 171:1871-1882 (1990); Carbonetti and Sparling, *Proc. Natl. Acad. Sci. USA* 84:9084-9088 (1987); Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629 (1992); Murakami, K., *et al.*, *Infect. Immun.* 57:2318-2323 (1989); Wolff and Stern, *FEMS Microbiol. Lett.* 83:179-186 (1991); Ward, M.J., *et al.*, *FEMS Microbiol. Lett.* 73:283-289 (1992)).

The porin proteins were initially co-isolated with lipopolysaccharides. Consequently, the porin proteins have been termed "endotoxin-associated proteins" (Bjornson *et al.*, *Infect. Immun.* 56:1602-1607 (1988)). Studies on the wild type porins have reported that full assembly and oligomerization are not achieved unless LPS from the corresponding bacterial strain is present in the protein environment

- 3 -

(Holzenburg *et al.*, *Biochemistry* 28:4187-4193 (1989); Sen and Nikaido, *J. Biol. Chem.* 266:11295-11300 (1991)).

The meningococcal porins have been subdivided into three major classifications which in antedated nomenclature were known as Class 1, 2, and 3 (Frasch, C.E., *et al.*, *Rev. Infect. Dis.* 7:504-510 (1985)). Each meningococcus examined has contained one of the alleles for either a Class 2 porin gene or a Class 3 porin gene but not both (Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629 (1992)); Murakami, K., *et al.*, *Infect. Immun.* 57:2318-2323 (1989)). The presence or absence of the Class 1 gene appears to be optional. Likewise, all probed gonococci contain only one porin gene with similarities to either the Class 2 or Class 3 allele (Gotschlich, E.C., *et al.*, *Proc. Natl. Acad. Sci. USA* 84:8135-8139 (1987); Carbonetti and Sparling, *Proc. Natl. Acad. Sci. USA* 84:9084-9088 (1987)). *N. gonorrhoeae* appear to completely lack the Class 1 allele. The data from the genes that have been thus far sequenced would suggest that all neisserial porin proteins have at least 70% homology with each other with some variations on a basic theme (Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629 (1992)). It has been suggested that much of the variation seen between these neisserial porin proteins is due to the immunological pressures brought about by the invasion of these pathogenic organisms into their natural host, man. However, very little is known about how the changes in the porin protein sequence effect the functional activity of these proteins.

It has been previously reported that isolated gonococcal porins of the Class 2 allelic type behave electrophysically somewhat differently than isolated gonococcal porins of the Class 3 type in lipid bilayer studies both in regards to their ion selectivity and voltage-dependence (Lynch, E.C., *et al.*, *Biophys. J.* 41:62 (1983); Lynch, E.C., *et al.*, *Biophys. J.* 45:104-107 (1984)). Furthermore, the ability of the different porins to enter these

- 4 -

lipid bilayers from intact living bacteria seems to correlate not only with the porin type but also with the neisserial species from which they were donated (Lynch, E.C., *et al.*, *Biophys. J.* 45:104-107 (1984)). It would seem that at least some of these functional attributes could be related to different areas within the protein sequence of the porin. One such functional area, previously identified within all gonococcal Class 2-like proteins, is the site of chymotrypsin cleavage. Upon chymotrypsin digestion, this class of porins lack the ability to respond to a voltage potential and close. Gonococcal Class 3-like porins as well as meningococcal porins lack this sequence and are thus not subject to chymotrypsin cleavage but nonetheless respond by closing to an applied voltage potential (Greco, F., "The formation of channels in lipid bilayers by gonococcal major outer membrane protein," thesis, The Rockefeller University, New York (1981); Greco, F., *et al.*, *Fed. Proc.* 39:1813 (1980)).

The major impediment for such studies has been the ability to easily manipulate the porin genes by modern molecular techniques and obtain sufficient purified protein to carry out the biophysical characterizations of these altered porin proteins. It was early recognized that cloned neisserial porin genes, when expressed in *Escherichia coli*, were lethal to the host *E. coli* (Carbonetti and Sparling, *Proc. Natl. Acad. Sci. USA* 84:9084-9088 (1987); Carbonetti, N.H., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6841-6845 (1988); Barlow, A.K., *et al.*, *Infect. Immun.* 55:2734-2740 (1987)). Thus, many of these genes were cloned and sequenced as pieces of the whole gene or placed into low copy number plasmids under tight expression control (Carbonetti, N.H., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6841-6845 (1988)). Under these conditions, even when the entire porin gene was expressed, very little protein accumulated that could be further purified and processed for characterization.

- 5 -

Another tack to this problem which has met with a modicum of success has been to clone the porin genes into a low copy, tightly controlled expression plasmid, introduce modifications to the porin gene, and then reintroduce the modified sequence back into *Neisseria* (Carbonetti, N.H., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6841-6845 (1988)). However, this has also been fraught with problems due to the elaborate restriction endonuclease system present in *Neisseria*, especially gonococci (Davies, J.K., *Clin. Microbiol. Rev.* 2:S78-S82 (1989)).

The present invention is directed to an approach to overcome these difficulties. The DNA sequence of the mature porin proteins, e.g. class 2 and class 3 as well as fusions thereof, may be amplified using the chromosome of the meningococcal bacteria as a template for the PCR reaction. The amplified porin sequences were ligated and cloned into an expression vector containing the T7 promoter. *E. coli* strain BL21 lysogenic for the DE3 lambda phage (Studier and Moffatt, *J. Mol. Biol.* 189:113-130 (1986)), modified to eliminate the *ompA* gene, was selected as one expression host for the pET-17b plasmid containing the porin gene. Upon induction, large amounts of the meningococcal porin proteins accumulated within the *E. coli* without any obvious lethal effects to the host bacterium. The expressed meningococcal porin proteins were extracted and processed through standard procedures and finally purified by molecular sieve chromatography and ion exchange chromatography. As judged by the protein profile from the molecular sieve chromatography, the recombinant meningococcal porins eluted from the column as trimers. To be certain that no PCR artifacts had been introduced into the meningococcal porin genes to allow for such high expression, the inserted PorB gene sequence was determined. Inhibition ELISA assays were used to give further evidence that the expressed recombinant porin proteins had renatured into their natural antigenic and trimer conformation.

Summary of the Invention

Porins from different neisserial strains and species have been shown to have differences in both primary amino acid sequence and biophysical characteristics as observed by functional assays. A closer examination of how the changes in the primary amino acid sequence of *Neisseria porin* molecules correlate with these observed biophysical changes has been impeded by the ability to easily manipulate the cloned porin genes by modern molecular techniques and then subsequently obtain enough of the expressed modified porin protein to purify and apply to these biophysical functional assays. In this invention, the gene coding for a mature PorB protein, lacking the neisserial promoter and signal sequence, was cloned into the expression plasmid pET-17b and transformed into *E. coli*. Upon induction, large amounts of the PorB protein was produced.

The expressed porin protein was then manipulated to regenerate its native trimer structure and was then purified. Sufficient purified recombinant porin protein was obtained for further antigenic as well as biophysical characterization. Thus, this sets the stage whereby the biophysical characterization of these neisserial porin proteins can be examined in more detail.

It is a general object of the invention to provide a method of expressing the meningococcal group B porin protein, in particular, the class 2 and class 3 porin proteins.

It is a specific object of the invention to provide a method of expressing the meningococcal group B class 2 or 3 porin protein in *E. coli* comprising:

- 7 -

(a) transforming *E. coli* by a vector comprising a selectable marker and a gene coding for a protein selected from the group consisting of

(i) a mature porin protein, and

(ii) a fusion protein comprising a mature porin protein fused to amino acids 1 to 20 of the T7 gene $\phi 10$ capsid protein;

wherein said gene is operably linked to the T7 promoter;

(b) growing the transformed *E. coli* in a culture media containing a selection agent, and

(c) inducing expression of said protein;

wherein the protein comprises more than 2% of the total protein expressed in the *E. coli*.

It is another specific object of the invention to provide a method of purifying and refolding a meningococcal group B porin protein and fusion protein produced according to the above-described methods.

It is a further specific object of the invention to provide a vaccine comprising the meningococcal group B porin protein and fusion protein, produced according to the above methods, in an amount effective to elicit protective antibodies in an animal to *Neisseria meningitidis*; and a pharmaceutically acceptable diluent, carrier, or excipient.

It is another specific object of the invention to provide the above-described vaccine, wherein said meningococcal group B porin protein or fusion protein is conjugated to a *Neisseria meningitidis* capsular polysaccharide.

It is a further specific object of the invention to provide a method of preventing bacterial meningitis in an animal comprising administering to the animal the meningococcal group B porin protein or fusion protein-vaccine produced according to the above-described methods.

- 8 -

It is another specific object of the invention to provide a method of preparing a polysaccharide conjugate comprising: obtaining the above-described meningococcal group B porin protein or fusion protein; obtaining a polysaccharide from a *Neisseria meningitidis* organism; and conjugating the meningococcal group B porin protein or fusion protein to the polysaccharide.

It is another specific object of the invention to provide a method of purifying the above-described meningococcal group B porin protein or fusion protein comprising: lysing the transformed *E. coli* to release the meningococcal group B porin protein or fusion protein as part of insoluble inclusion bodies; washing the inclusion bodies with a buffer to remove contaminating *E. coli* cellular proteins; resuspending and dissolving the inclusion bodies in an aqueous solution of a denaturant; diluting the resultant solution in a detergent; and purifying the solubilized meningococcal group B porin protein or fusion protein by gel filtration and ion exchange chromatography.

It is another specific object of the invention to provide a method of refolding the above-described meningococcal group B porin protein or fusion protein comprising: lysing the transformed *E. coli* to release the meningococcal group B porin protein or fusion protein as part of insoluble inclusion bodies; washing the inclusion bodies with a buffer to remove contaminating *E. coli* cellular proteins; resuspending and dissolving the inclusion bodies in an aqueous solution of a denaturant; diluting the resultant solution in a detergent; and purifying the solubilized meningococcal group B porin protein or fusion protein by gel filtration to give the refolded protein in the eluant.

It is another specific object of the invention to provide an *E. coli* strain BL21 (DE3) $\Delta ompA$ host cell that contains a vector which comprises a DNA molecule coding for a meningococcal group B porin protein or

- 9 -

fusion protein, wherein the DNA molecule is operably linked to the T7 promotor of the vector.

It is another specific object of the invention to provide the *E. coli* strain BL21(DE3) $\Delta ompA$.

5 Further objects and advantages of the present invention will be clear from the description that follows.

Brief Description of the Drawings

10 **Figure 1:** A diagram showing the sequencing strategy of the *PorB* gene. The PCR product described in Example 1 (Materials and Methods section) was ligated into the *Bam*HI-*Xho*I site of the expression plasmid pET-17b. The initial double stranded primer extension sequencing was accomplished using oligonucleotide sequences directly upstream of the *Bam*HI site and just downstream of the *Xho*I site within the pET-17b plasmid. Additional sequence data was obtained by making numerous
15 deletions in the 3' end of the gene, using exonuclease III/mung bean nuclease reactions. After religation and transformation back into *E. coli*, several clones were selected on size of insert and subsequently sequenced. This sequencing was always from the 3' end of the gene using an oligonucleotide primer just downstream of the *Bpu*11021 site.

20 **Figure 2:** A gel electrophoresis showing the products of the PCR reaction (electrophoresed in a 1% agarose using TAE buffer).

Figure 3 (panels (a) and (b)). Panel (a): SDS-PAGE analysis of whole cell lysates of *E. coli* hosting the control pET-17b plasmid without inserts and an *E. coli* clone harboring pET-17b plasmid containing an insert
25 from the obtained PCR product described in the materials and methods section. Both cultures were grown to an O.D. of 0.6 at 600 nm, IPTG added, and incubated at 37°C for 2 hrs. 1.5 mls of each of the cultures

- 10 -

were removed, centrifuged, and the bacterial pellet solubilized in 100 μ l of SDS-PAGE preparation buffer. Lane A shows the protein profile obtained with 10 μ l from the control sample and Lanes B (5 μ l) and C (10 μ l) demonstrate the protein profile of the *E. coli* host expressing the PorB protein. Panel (b): Western blot analysis of whole cell lysates of *E. coli* harboring the control pET-17b plasmid without insert after 2 hrs induction with IPTG, Lane A, 20 μ l and a corresponding *E. coli* clone containing a porB-pET-17b plasmid, Lane B, 5 μ l; Lane C, 10 μ l; and Lane D, 20 μ l. The monoclonal antibody 4D11 was used as the primary antibody and the western blot developed as described. The pre-stained low molecular weight standards from BRL were used in each case.

Figure 4: The nucleotide sequence (SEQ ID NO. 1) and the translated amino acid sequence (SEQ ID NO. 2) of the mature *PorB* gene cloned into the expression plasmid pET-17b. The two nucleotides which differ from the previously published serotype 15 *PorB* are underlined.

Figure 5: A graph showing the Sephacryl S-300 column elution profile of both the wild type Class 3 protein isolated from the meningococcal strain 8765 and the recombinant Class 3 protein produced by BL21(DE3) - $\Delta ompA$ *E. coli* strain hosting the r3pET-17b [is this a typo - it does not appear in the Examples] plasmid as monitored by absorption at 280nm and SDS-PAGE analysis. The void volume of the column is indicated by the arrow. Fractions containing the meningococcal porin and recombinant porin as determined by SDS-PAGE are noted by the bar.

Figure 6: A graph showing the results of the inhibition ELISA assays showing the ability of the homologous wild type (wt) PorB to compete for reactive antibodies in six human immune sera. The arithmetic mean inhibition is shown by the bold line.

Figure 7: A graph showing the results of the inhibition ELISA assays showing the ability of the purified recombinant PorB protein to

- 11 -

compete for reactive antibodies in six human immune sera. The arithmetic mean inhibition is shown by the bold line.

Figure 8: A graph showing a comparison of these two mean inhibitions obtained with the wt and recombinant PorB protein.

5 **Figure 9A and 9B:** The nucleotide sequence (SEQ ID NO. 3) and the translated amino acid sequence (SEQ ID NO. 4) of the mature class II porin gene cloned into the expression plasmid pET-17b.

10 **Figure 10A and 10B:** The nucleotide sequence (SEQ ID NO. 5) and the translated amino acid sequence (SEQ ID NO. 6) of the fusion class II porin gene cloned into the expression plasmid pET-17b.

15 **Figure 11 (panels A and B):** Panel A depicts the restriction map of the pET-17b plasmid. Panel B depicts the nucleotide sequence (SEQ ID NO. 7 AND SEQ ID NO. 9) between the *Bgl*III and *Xho*I sites of pET-17b. The sequence provided by the plasmid is in normal print while the sequence inserted from the PCR product are identified in bold print. The amino acids (SEQ ID NO. 8 AND SEQ ID NO. 10) which are derived from the plasmid are in normal print while the amino acids from the insert are in bold. The arrows demarcate where the sequence begins to match the sequence in Figure 4 and when it ends.

20

Detailed Description of the Invention

25 Unlike the porin proteins of *E. coli* and a few other gram negative bacteria, relatively little is known how changes in the primary sequence of porins from *Neisseria* effect their ion selectivity, voltage dependence, and other biophysical functions. Recently, the crystalline structure of two *E. coli* porins, OmpF and PhoE, were solved to 2.4Å and 3.0Å, respectively (Cowan, S.W., *et al.*, *Nature* 358:727-733 (1992)). Both of these *E. coli* porins have been intensively studied owing to their unusual

- 12 -

stability and ease with which molecular genetic manipulations could be accomplished. The data obtained for the genetics of these two porins correlated well with the crystalline structure. Although it has been shown in several studies, using monoclonal antibodies to select neisserial porins, that the surface topology of *Neisseria* closely resembles that of these two *E. coli* porins (van der Ley, P., *et al.*, *Infect. Immun.* 59:2963-2971 (1991)), almost no information is available about how changes in amino acid sequences in specific areas of the neisserial porins effect their biophysical characteristics, as had been done with the *E. coli* porins (Cowan, S.W., *et al.*, *Nature* 358:727-733 (1992)).

Two of the major problems impeding this research are: (1) the inability to easily manipulate *Neisseria* genetically by modern molecular techniques and (2) the inability to express sufficient quantities of neisserial porins in *E. coli* for further purification to obtain biophysical and biochemical characterization data. In fact, most of the DNA sequence data on gonococcal and meningococcal porins have been obtained by cloning overlapping pieces of the porin gene and then reconstructing the information to reveal the entire gene sequence (Gotschlich, E.C., *et al.*, *Proc. Natl. Acad. Sci. USA* 84:8135-8139 (1987); Murakami, K., *et al.*, *Infect. Immun.* 57:2318-2323 (1989)). Carbonetti *et al.* were the first to clone an entire gonococcal porin gene into *E. coli* using a tightly controlled pT7-5 expression plasmid. The results of these studies showed that when the porin gene was induced, very little porin protein accumulated and the expression of this protein was lethal to the *E. coli* (Carbonetti and Sparling, *Proc. Natl. Acad. Sci. USA* 84:9084-9088 (1987)). In additional studies, Carbonetti *et al.* (*Proc. Natl. Acad. Sci. USA* 85:6841-6845 (1988)) did show that alterations in the gonococcal porin gene could be made in this system in *E. coli* and then reintroduced into gonococci. However, the ease with which one can make these manipulations and obtain enough porin

- 13 -

protein for further biochemical and biophysical characterization seems limited.

Feavers *et al.* have described a method to amplify, by PCR, neisserial porin genes from a wide variety of sources using two synthesized oligonucleotides to common domains at the 5' and 3' ends of the porin genes respectively (Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629 (1992)). The oligonucleotides were constructed such that the amplified DNA could be forced cloned into plasmids using the restriction endonucleases *Bgl*II and *Xho*I.

Using the Feavers *et al.* PCR system, the DNA sequence of the mature PorB protein from meningococcal strain 8765 serotype 15 was amplified and ligated into the *Bam*HI-*Xho*I site of the T7 expression plasmid pET-17b. This placed the mature PorB protein sequence in frame directly behind the T7 promoter and 20 amino acids of the ϕ 10 protein including the leader sequence. Upon addition of IPTG to a culture of *E. coli* containing this plasmid, large amounts of PorB protein accumulated within the bacteria. A complete explanation for why this construction was non-lethal to the *E. coli* and expressed large amount of the porin protein, await further studies. However, one possible hypothesis is that by replacing the neisserial promoter and signal sequence with that of the T7 and ϕ 10 respectively, the porin product was directed to the cytoplasm rather than toward the outer membrane. Henning and co-workers have reported that when *E. coli* OmpA protein and its fragments are expressed, those products which are found in the cytoplasm are less toxic than those directed toward the periplasmic space (Klose, M., *et al.*, *J. Biol. Chem.* 263:13291-13296 (1988); Klose, M., *et al.*, *J. Biol. Chem.* 263:13297-13302 (1988); Freudl, R., *et al.*, *J. Mol. Biol.* 205:771-775 (1989)). Whatever the explanation, once the PorB protein was expressed, it was easily isolated, purified and appeared to reform into trimers much like the

- 14 -

native porin. The results of the inhibition ELISA data using human immune sera suggests that the PorB protein obtained in this fashion regains most if not all of the antigenic characteristics of the wild type PorB protein purified from meningococci. This expression system lends itself to the easy manipulation of the neisserial porin gene by modern molecular techniques. In addition, this system allows one to obtain large quantities of pure porin protein for characterization. In addition, the present expression system allows the genes from numerous strains of *Neisseria*, both gonococci and meningococci, to be examined and characterized in a similar manner.

Thus, the present invention relates to a method of expressing an outer membrane meningococcal group B porin protein, in particular, the class 2 and class 3 porin proteins.

In one embodiment, the present invention relates to a method of expressing the outer membrane meningococcal group B porin protein in *E. coli* comprising:

(a) transforming *E. coli* by a vector comprising a selectable marker and a gene coding for a protein selected from the group consisting of:

(i) a mature porin protein, and

(ii) a fusion protein comprising a mature porin protein fused to amino acids 1 to 20 or 22 of the T7 gene $\phi 10$ capsid protein;

wherein said gene is operably linked to the T7 promoter;

(b) growing the transformed *E. coli* in a culture media containing a selection agent, and

(c) inducing expression of said protein;

wherein the protein so produced comprises more than about 2% of the total protein expressed in the *E. coli*.

- 15 -

In a preferred embodiment, the meningococcal group B porin protein or fusion protein expressed comprises more than about 5% of the total proteins expressed in *E. coli*. In another preferred embodiment, the meningococcal group B porin protein or fusion protein expressed comprises more than about 10% of the total proteins expressed in *E. coli*. In yet another preferred embodiment, the meningococcal group B porin protein or fusion protein expressed comprises more than about 30% of the total proteins expressed in *E. coli*.

Examples of plasmids which contain the T7 inducible promotor include the expression plasmids pET-17b, pET-11a, pET-24a-d(+) and pET-9a, all of which are commercially available from Novagen (565 Science Drive, Madison, WI 53711). These plasmids comprise, in sequence, a T7 promoter, optionally a lac operator, a ribosome binding site, restriction sites to allow insertion of the structural gene and a T7 terminator sequence. See, the Novagen catalogue, pages 36-43 (1993).

In a preferred embodiment, *E. coli* strain BL21 (DE3) $\Delta ompA$ is employed. The above mentioned plasmids may be transformed into this strain or the wild-type strain BL21(DE3). *E. coli* strain BL21 (DE3) $\Delta ompA$ is preferred as no OmpA protein is produced by this strain which might contaminate the purified porin protein and create undesirable immunogenic side effects.

The transformed *E. coli* are grown in a medium containing a selection agent, e.g. any β -lactam to which *E. coli* is sensitive such as ampicillin. The pET expression vectors provide selectable markers which confer antibiotic resistance to the transformed organism.

High level expression of meningococcal group B porin protein can be toxic in *E. coli*. Surprisingly, the present invention allows *E. coli* to express the protein to a level of at least almost 30% and as high as >50% of the total cellular proteins.

- 16 -

In another preferred embodiment, the present invention relates to a vaccine comprising the outer membrane meningococcal group B porin protein or fusion protein thereof, produced according to the above-described methods, together with a pharmaceutically acceptable diluent, carrier, or excipient, wherein the vaccine may be administered in an amount effective to elicit protective antibodies in an animal to *Neisseria meningitidis*. In a preferred embodiment, the animal is selected from the group consisting of humans, cattle, pigs, sheep, and chickens. In another preferred embodiment, the animal is a human.

In another preferred embodiment, the present invention relates to the above-described vaccine, wherein said outer membrane meningococcal group B porin protein or fusion protein thereof is conjugated to a meningococcal group B capsular polysaccharide (CP). Such capsular polysaccharides may be prepared as described in Ashton, F.E. *et al.*, *Microbial Pathog.* 6:455-458 (1989); Jennings, H.J. *et al.*, *J. Immunol.* 134:2651 (1985); Jennings, H.J. *et al.*, *J. Immunol.* 137:1708-1713 (1986); Jennings, H.J. *et al.*, *J. Immunol.* 142:3585-3591 (1989); Jennings, H.J., "Capsular Polysaccharides as Vaccine Candidates," in *Current Topics in Microbiology and Immunology*, 150:105-107 (1990); the contents of each of which are fully incorporated by reference herein.

Preferably, the CP is isolated according to Frasch, C.E., "Production and Control of *Neisseria meningitidis* Vaccines" in *Bacterial Vaccines*, Alan R. Liss, Inc., pages 123-145 (1990), the contents of which are fully incorporated by reference herein, as follows:

Grow organisms in modified Franz medium 10 to 20 hrs

↓ Heat kill, 55°C, 10 min

Remove inactivated cells by centrifugation

↓ Add Cetavlon to 0.1 %

Precipitate CP from culture broth

- 17 -

↓ Add calcium chloride to 1 M

Dissolve CP then centrifuge to remove cellular debris

↓ Add ethyl alcohol to 25 %

Remove precipitated nucleic acids by centrifugation

5

↓ Add ethyl alcohol to 80 %

Precipitate crude CP and remove alcohol

The crude CP is then further purified by gel filtration chromatography after partial depolymerization with dilute acid, e.g.

10

acetic acid, formic acid, and trifluoroacetic acid (0.01-0.5 N), to give a mixture of polysaccharides having an average molecular weight of 12,000-16,000. The CP is then N-deacetylated with borohydride and N-propionylated to afford N-Pr GBMP. Thus, the CP that may be employed in the conjugate vaccines of the present invention may be CP fragments, N-deacylated CP and fragments thereof, as well as N-Pr CP and fragments thereof, so long as they induce active immunity when employed as part of a CP-porin protein conjugate (see the Examples).

15

In a further preferred embodiment, the present invention relates to a method of preparing a polysaccharide conjugate comprising: obtaining the above-described outer membrane meningococcal group B porin protein or fusion protein thereof; obtaining a CP from a *Neisseria meningitidis* organism; and conjugating the protein to the CP.

20

The conjugates of the invention may be formed by reacting the reducing end groups of the CP to primary amino groups of the porin by reductive amination. The reducing groups may be formed by selective hydrolysis or specific oxidative cleavage, or a combination of both. Preferably, the CP is conjugated to the porin protein by the method of Jennings *et al.*, U.S. Patent No. 4,356,170, the contents of which are fully

25

- 18 -

incorporated by reference herein, which involves controlled oxidation of the CP with periodate followed by reductive amination with the porin protein.

The vaccine of the present invention comprises the meningococcal group B porin protein, fusion protein or conjugate vaccine in an amount effective depending on the route of administration. Although subcutaneous or intramuscular routes of administration are preferred, the meningococcal group B porin protein, fusion protein or vaccine of the present invention can also be administered by an intraperitoneal or intravenous route. One skilled in the art will appreciate that the amounts to be administered for any particular treatment protocol can be readily determined without undue experimentation. Suitable amounts might be expected to fall within the range of 2 micrograms of the protein per kg body weight to 100 micrograms per kg body weight.

The vaccine of the present invention may be employed in such forms as capsules, liquid solutions, suspensions or elixirs for oral administration, or sterile liquid forms such as solutions or suspensions. Any inert carrier is preferably used, such as saline, phosphate-buffered saline, or any such carrier in which the meningococcal group B porin protein, fusion protein or conjugate vaccine have suitable solubility properties. The vaccines may be in the form of single dose preparations or in multi-dose flasks which can be used for mass vaccination programs. Reference is made to Remington's *Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, Osol (ed.) (1980); and *New Trends and Developments in Vaccines*, Voller *et al.* (eds.), University Park Press, Baltimore, MD (1978), for methods of preparing and using vaccines.

The meningococcal group B porin protein, fusion protein or conjugate vaccines of the present invention may further comprise adjuvants which enhance production of porin-specific antibodies. Such adjuvants include, but are not limited to, various oil formulations such as Freund's

- 19 -

complete adjuvant (CFA), stearyl tyrosine (ST, *see* U.S. Patent No. 4,258,029), the dipeptide known as MDP, saponin, aluminum hydroxide, and lymphatic cytokine.

5 Freund's adjuvant is an emulsion of mineral oil and water which is mixed with the immunogenic substance. Although Freund's adjuvant is powerful, it is usually not administered to humans. Instead, the adjuvant alum (aluminum hydroxide) or ST may be used for administration to a human. The meningococcal group B porin protein or a conjugate vaccine thereof may be absorbed onto the aluminum hydroxide from which it is
10 slowly released after injection. The meningococcal group B porin protein or conjugate vaccine may also be encapsulated within liposomes according to Fullerton, U.S. Patent No. 4,235,877.

In another preferred embodiment, the present invention relates to a method of preventing bacterial meningitis in an animal comprising
15 administering to the animal the meningococcal group B porin protein, fusion protein or conjugate vaccine produced according to methods described in an amount effective to prevent bacterial meningitis.

In a further embodiment, the invention relates to a method of purifying the above-described outer membrane meningococcal group B
20 porin protein or fusion protein comprising: lysing the transformed *E. coli* to release the meningococcal group B porin protein or fusion protein as part of insoluble inclusion bodies; washing the inclusion bodies with a buffer to remove contaminating *E. coli* cellular proteins; resuspending and dissolving the inclusion bodies in an aqueous solution of a denaturant;
25 diluting the resultant solution in a detergent; and purifying the solubilized meningococcal group B porin protein by gel filtration.

The lysing step may be carried out according to any method known to those of ordinary skill in the art, e.g. by sonication, enzyme digestion, osmotic shock, or by passing through a mull press.

- 20 -

The inclusion bodies may be washed with any buffer which is capable of solubilizing the *E. coli* cellular proteins without solubilizing the inclusion bodies comprising the meningococcal group B porin protein. Such buffers include but are not limited to TEN buffer (50 mM Tris HCl, 1 mM EDTA, 100 mM NaCl, pH 8.0), Tricine, Bicine and HEPES.

Denaturants which may be used in the practice of the invention include 2 to 8 M urea or about 2 to 6 M guanidine HCl, more preferably, 4 to 8 M urea or about 4 to 6 M guanidine HCl, and most preferably, about 8 M urea or about 6 M guanidine HCl).

Examples of detergents which can be used to dilute the solubilized meningococcal group B porin protein include, but are not limited to, ionic detergents such as SDS and cetavlon (Calbiochem); non-ionic detergents such as Tween, Triton X, Brij 35 and octyl glucoside; and zwitterionic detergents such as 3,14-Zwittergent, empigen BB and Champs.

Finally, the solubilized outer membrane meningococcal group B porin protein may be purified by gel filtration to separate the high and low molecular weight materials. Types of filtration gels include but are not limited to Sephacryl-300, Sepharose CL-6B, and Bio-Gel A-1.5m. The column is eluted with the buffer used to dilute the solubilized protein. The fractions containing the porin or fusion thereof may then be identified by gel electrophoresis, the fractions pooled, dialyzed, and concentrated.

Finally, substantially pure (> 95%) porin protein and fusion protein may be obtained by passing the concentrated fractions through a Q sepharose high performance column.

In another embodiment, the present invention relates to expression of the meningococcal group B porin protein gene which is part of a vector which comprises the T7 promoter, which is inducible. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. The T7 promoter is inducible by the addition of

- 21 -

isopropyl β -D-thiogalactopyranoside (IPTG) to the culture medium. Alternatively, the Tac promotor or heat shock promotor may be employed.

Preferably, the meningococcal group B porin protein gene is expressed from the pET-17 expression vector or the pET-11a expression vector, both of which contain the T7 promoter.

The cloning of the meningococcal group B porin protein gene or fusion gene into an expression vector may be carried out in accordance with conventional techniques, including blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Reference is made to Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press (1989), for general methods of cloning.

The meningococcal group B porin protein and fusion protein expressed according to the present invention must be properly refolded in order to achieve a structure which is immunologically characteristic of the native protein. In yet another embodiment, the present invention relates to a method of refolding the above-described outer membrane protein and fusion protein comprising: lysing the transformed *E. coli* to release the meningococcal group B porin protein or fusion protein as part of insoluble inclusion bodies; washing the inclusion bodies with a buffer to remove contaminating *E. coli* cellular proteins; resuspending and dissolving the inclusion bodies in an aqueous solution of a denaturant; diluting the resultant solution in a detergent; and purifying the solubilized meningococcal group B porin protein or fusion protein by gel filtration to give the refolded protein in the eluant. Surprisingly, it has been discovered that the folded trimeric meningococcal group B class 2 and class 3 porin

- 22 -

proteins and fusion proteins are obtained directly in the eluant from the gel filtration column.

In another preferred embodiment, the present invention relates to a substantially pure refolded outer membrane meningococcal group B porin protein and fusion protein produced according to the above-described methods. A substantially pure protein is a protein that is generally lacking in other cellular *Neisseria meningitidis* components as evidenced by, for example, electrophoresis. Such substantially pure proteins have a purity of >95%, as measured by densitometry on an electrophoretic gel after staining with Coomassie blue or silver stains.

The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in this art which are obvious to those skilled in the art are within the spirit and scope of the present invention.

Examples

Example 1. Cloning of the Class 3 Porin Protein from Group B *Neisseria meningitidis*

Materials and Methods

Organisms: The Group B *Neisseria meningitidis* strain 8765 (B:15:P1,3) was obtained from Dr. Wendell Zollinger (Walter Reed Army Institute for Research) and grown on agar media previously described (Swanson, J.L., *Infect. Immun.* 21:292-302 (1978)) in a candle extinction jar in an incubator maintained at 30°C. *Escherichia coli* strains DME558 (from the collection of S. Benson; Silhavy, T.J. *et al.*, "Experiments with Gene Fusions," Cold Spring Harbor Laboratory, Cold Spring Harbor,

- 23 -

N.Y., 1984), BRE51 (Bremer, E. *et al.*, *FEMS Microbiol. Lett.* 33:173-178 (1986)) and BL21(DE3) were grown on LB agar plates at 37°C.

P1 Transduction: A P1_{vir} lysate of *E. coli* strain DME558 was used to transduce a tetracycline resistance marker to strain BRE51 (Bremer, E., *et al.*, *FEMS Microbiol. Lett.* 33:173-178 (1986)) in which the entire *ompA* gene had been deleted (Silhavy, T.J., *et al.*, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984)). Strain DME558, containing the tetracycline resistance marker in close proximity of the *ompA* gene, was grown in LB medium until it reached a density of approximately 0.6 OD at 600 nm. One tenth of a milliliter of 0.5 M CaCl₂ was added to the 10 ml culture and 0.1 ml of a solution containing 1 x 10⁹ PFU of P1_{vir}. The culture was incubated for 3 hours at 37°C. After this time, the bacterial cell density was visibly reduced. 0.5 ml of chloroform was added and the phage culture stored at 4°C. Because typically 1-2% of the *E. coli* chromosome can be packaged in each phage, the number of phage generated covers the entire bacterial host chromosome, including the tetracycline resistance marker close to the *ompA* gene.

Next, strain BRE51, which lacks the *ompA* gene, was grown in LB medium overnight at 37°C. The overnight culture was diluted 1:50 into fresh LB and grown for 2 hr. The cells were removed by centrifugation and resuspended in MC salts. 0.1 ml of the bacterial cells were mixed with 0.05 of the phage lysate described above and incubated for 20 min. at room temperature. Thereafter, an equal volume of 1 M sodium citrate was added and the bacterial cells were plated out onto LB plates containing 12.5 µg/ml of tetracycline. The plates were incubated overnight at 37°C. Tetracycline resistant (12 µg/ml) transductants were screened for lack of OmpA protein expression by SDS-PAGE and Western Blot analysis, as described below. The bacteria resistant to the antibiotic have the

- 24 -

tetracycline resistance gene integrated into the chromosome very near where the *ompA* gene had been deleted from this strain. One particular strain was designated BRE-T^R.

5 A second round of phage production was then carried out with the strain BRE-T^R, using the same method as described above. Representatives of this phage population contain both the tetracycline resistance gene and the OmpA deletion. These phage were then collected and stored. These phage were then used to infect *E. coli* BL21(DE3). After infection, the bacteria contain the tetracycline resistance marker. In addition, there is a
10 high probability that the OmpA deletion was selected on the LB plates containing tetracycline.

Colonies of bacteria which grew on the plates were grown up separately in LB medium and tested for the presence of the OmpA protein. Of those colonies selected for examination, all lacked the OmpA protein as
15 judged by antibody reactivity on SDS-PAGE western blots.

SDS-PAGE and Western Blot: The SDS-PAGE was a variation of Laemmli's method (Laemmli, U.K., *Nature* 227:680-685 (1970)) as described previously (Blake and Gotschlich, *J. Exp. Med.* 159:452-462 (1984)). Electrophoretic transfer to Immobilon P (Millipore Corp. Bedford,
20 MA) was performed according to the methods of Towbin *et al.* (Towbin, H., *et al.*, *Proc. Natl. Acad. Sci. USA* 76:4350-4354 (1979)) with the exception that the paper was first wetted in methanol. The Western blots were probed with phosphatase conjugated reagents (Blake, M.S., *et al.*, *Analyt. Biochem.* 136:175-179 (1984)).

25 **Polymerase Chain Reaction:** The method described by Feavers *et al.* (Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629 (1992)) was used to amplify the gene encoding the PorB. The primers selected were primers 33 (SEQ ID NO. 11) (GGG GTA GAT CTG CAG GTT ACC TTG TAC GGT ACA ATT AAA GCA GGC GT) and 34 (SEQ ID NO. 12) (GGG

- 25 -

GGG GTG ACC CTC GAG TTA GAA TTT GTG ACG CAG ACC AAC)
as previously described (Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629
(1992)). Briefly, the reaction components were as follows: Meningococcal
strain 8765 chromosomal DNA (100 ng/ μ l), 1 μ l; 5' and 3' primers (1 μ M)
5 2 μ l each; dNTP (10 mM stocks), 4 μ l each; 10 X PCR reaction buffer
(100 mM Tris HCl, 500 mM KCl, pH 8.3), 10 μ l; 25 mM MgCl₂, 6 μ l;
double distilled H₂O, 62 μ l; and Taq polymerase (Cetus Corp., 5 u/ μ l), 1
 μ l. The reaction was carried out in a GTC-2 Genetic Thermocycler
(Precision Inst. Inc, Chicago, IL) connected to a Lauda 4/K methanol/water
10 cooling system (Brinkman Instruments, Inc., Westbury, NY) set at 0°C.
The thermocycler was programmed to cycle 30 times through: 94°C, 2
min.; 40°C, 2 min.; and 72°C, 3 min. At the end of these 30 cycles, the
reaction was extended at 72°C for 3 min and finally held at 4°C until
readied for analysis on a 1% agarose gel in TAE buffer as described by
15 Maniatis (Maniatis, T., *et al.*, *Molecular Cloning, A Laboratory Manual*,
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982)).

Subcloning of the PCR product: The pET-17b plasmid (Novagen,
Inc.) was used for subcloning and was prepared by double digesting the
plasmid with the restriction endonucleases *Bam*HI and *Xho*I (New England
20 Biolabs, Inc., Beverly, MA). The digested ends were then
dephosphorylated with calf intestinal alkaline phosphatase (Boehringer
Mannheim, Indianapolis, IN). The digested plasmid was then analyzed on
a 1% agarose gel, the cut plasmid removed, and purified using the
GeneClean kit (Bio101, La Jolla, CA). The PCR product was prepared by
25 extraction with phenol-chloroform, chloroform, and finally purified using
the GeneClean Kit (Bio101). The PCR product was digested with
restriction endonucleases *Bgl*III and *Xho*I (New England Biolabs, Inc.).
The DNA was then extracted with phenol-chloroform, precipitated by
adding 0.1 volumes of 3 M sodium acetate, 5 μ l glycogen (20 μ g/ μ l), and

- 26 -

2.5 volumes of ethanol. After washing the DNA with 70% ethanol (vol/vol), it was redissolved in TE buffer. The digested PCR product was ligated to the double digested pET-17b plasmid described above using the standard T4 ligase procedure at 16°C overnight (*Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1993)). The ligation product was then transformed into the BL21 (DE3)- $\Delta ompA$ described above which were made competent by the method of Chung *et al.* (Chung, C.T., *et al.*, *Proc. Natl. Acad. Sci. USA* 86:2172-2175 (1989)). The transformants were selected on LB plates containing 50 μ g/ml carbenicillin and 12 μ g/ml tetracycline. Several transformants were selected, cultured in LB both containing carbenicillin and tetracycline for 6 hours at 30°C, and plasmid gene expression induced by the addition of IPTG. The temperature was raised to 37°C and the cultures continued for an additional 2 hrs. The cells of each culture were collected by centrifugation, whole cell lysates prepared, and analyzed by SDS-PAGE and Western Blot using a monoclonal antibody (4D11) which reacts with all neisserial porins.

Nucleotide Sequence Analysis: The nucleotide sequences of the cloned Class 3 porin gene DNA were determined by the dideoxy method using denatured double-stranded plasmid DNA as the template as described (*Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1993)). Sequenase II kits (United States Biochemical Corp., Cleveland, OH) were used in accordance with the manufacturer's instructions. The three synthesized oligonucleotide primers (Operon Technologies, Inc., Alameda, CA) were used for these reactions. One for the 5' end (SEQ ID NO. 13) which consisted of 5'TCAAGCTTGGTACCGAGCTC and two for the 3' end, (SEQ ID NO. 14) 5'TTTGTTAGCAGCCGGATCTG (SEQ ID NO. 15) and 5' CTCAAGACCCGTTTAGAGGCC. Overlapping, nested deletions were made by linearizing the plasmid DNA by restriction endonuclease *Bpu*11021 and the ends blunted by the addition of Thio-dNTP

- 27 -

and Klenow polymerase (*Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1993)). The linearized plasmid was then cleaved with restriction endonuclease *XhoI* and the *exoII*/Mung bean nuclease deletion kit used to make 3' deletions of the plasmid (Stratagene, Inc., La Jolla, CA) as instructed by the supplier. A map of this strategy is shown in Figure 1.

Expression and purification of the PorB gene product: Using a sterile micropipette tip, a single colony of the BL21 (DE3)- $\Delta ompA$ containing the PorB-pET-17b plasmid was selected and inoculated into 10 ml of LB broth containing 50 μ g/ml carbenicillin. The culture was incubated overnight at 30°C while shaking. The 10 ml overnight culture was then sterily added to 1 liter of LB broth with the same concentration of carbenicillin, and the culture continued in a shaking incubator at 37°C until the OD₆₀₀ reached 0.6-1.0. Three mls of a stock solution of IPTG (100 mM) was added to the culture and the culture incubated for an additional 30 min. Rifampicin was then added (5.88 ml of a stock solution; 34 mg/ml in methanol) and the culture continued for an additional 2 hrs. The cells were harvested by centrifugation at 10,000 rpm in a GS3 rotor for 10 min and weighed. The cells were thoroughly resuspended in 3 ml of TEN buffer (50 mM Tris HCl, 1 mM Tris HCl, 1 mM EDTA, 100 mM NaCl, pH 8.0) per gram wet weight of cells. To this was added 8 μ l of PMSF stock solution (50 mM in anhydrous ethanol) and 80 μ l of a lysozyme stock solution (10 mg/ml in water) per gram wet weight of cells. This mixture was stirred at room temperature for 20 min. While stirring, 4 mg per gram wet weight of cells of deoxycholate was added. The mixture was placed in a 37°C water bath and stirred with a glass rod. When the mixture became viscous, 20 μ l of DNase I stock solution (1 mg/ml) was added per gram weight wet cells. The mixture was then removed from the water bath and left at room temperature until the solution

- 28 -

was no longer viscous. The mixture was then centrifuged at 15,000 rpm in a SS-34 rotor for 20 min at 4°C. The pellet was retained and thoroughly washed twice with TEN buffer. The pellet was then resuspended in freshly prepared TEN buffer containing 0.1 mM PMSF and 8 M urea and sonicated in a bath sonicator (Heat Systems, Inc., Plainview, NY). The protein concentration was determined using a BCA kit (Pierce, Rockville, IL) and the protein concentration adjusted to less than 10 mg/ml using the TEN-urea buffer. The sample was then diluted 1:1 with 10% (weight/vol) Zwittergent 3,14 (CalBiochem, La Jolla, CA), sonicated, and loaded onto a Sephacryl S-300 molecular sieve column. The Sephacryl S-300 column (2.5 cm x 200 cm) had previously equilibrated with 100 mM Tris HCl, 200 mM NaCl, 10 mM EDTA, 0.05% Zwittergent 3,14, and 0.02% azide, pH 8.0. The column flow rate was adjusted to 8 ml/hr and 10 ml fractions were collected. The OD₂₈₀ of each fraction was measured and SDS-PAGE analysis performed on protein containing fractions.

Inhibition ELISA Assays: Microtiter plates (Nunc-Immuno Plate IIF, Nunc, Inc., Naperville, IL) were sensitized by adding 0.1 ml per well of porB (2 µg/ml) purified from the wild type strain 8765, in 0.1 M carbonate buffer, pH 9.6 with 0.02% azide. The plates were incubated overnight at room temperature. The plates were washed five times with 0.9% NaCl, 0.05% Brij 35, 10 mM sodium acetate pH 7.0, 0.02% azide. Human immune sera raised against the Type 15 Class 3 PorB protein was obtained from Dr. Phillip O. Livingston, Memorial-Sloan Kettering Cancer Center, New York, N.Y. The human immune sera was diluted in PBS with 0.5% Brij 35 and added to the plate and incubated for 2 hr at room temperature. The plates were again washed as before and the secondary antibody, alkaline phosphatase conjugated goat anti-human IgG (Tago Inc., Burlingame, CA), was diluted in PBS-Brij, added to the plates and incubated for 1 hr at room temperature. The plates were washed as before

- 29 -

and *p*-nitrophenyl phosphate (Sigma Phosphatase Substrate 104) (1 mg/ml) in 0.1 diethanolamine, 1 mM MgCl₂, 0.1 mM ZnCl₂, 0.02% azide, pH 9.8, was added. The plates were incubated at 37°C for 1 h and the absorbance at 405 nm determined using an Elida-5 microtiter plate reader (Physica, New York, NY). Control wells lacked either the primary and/or secondary antibody. This was done to obtain a titer for each human serum which would give a half-maximal reading in the ELISA assay. This titer for each human serum would be used in the inhibition ELISA. The ELISA microtiter plate would be sensitized with purified wild type PorB protein and washed as before. In a separate V-96 polypropylene microtiter plate (Nunc, Inc.), varying amounts of either purified wild type PorB protein or the purified recombinant PorB protein were added in a total volume of 75 µl. The human sera were diluted in PBS-Brij solution to twice their half maximal titer and 75 µl added to each of the wells containing the PorB or recombinant PorB proteins. This plate was incubated for 2 hr at room temperature and centrifuged in a Sorvall RT6000 refrigerated centrifuge, equipped with microtiter plate carriers (Wilmington, DE) at 3000 rpm for 10 min. Avoiding the V-bottom, 100 µl from each well was removed and transferred to the sensitized and washed ELISA microtiter plate. The ELISA plates are incubated for an additional 2 hr, washed, and the conjugated second antibody added as before. The plate is then processed and read as described. The percentage of inhibition is then processed and read as described. The percentage of inhibition is calculated as follows:

$$\frac{1 - (\text{ELISA value with either PorB or rPorB protein added})}{(\text{ELISA value without the porB added})} \times 100$$

Results

Polymerase Chain Reaction and Subcloning: A method to easily clone, genetically manipulate, and eventually obtain enough pure porin protein from any number of different neisserial porin genes for further antigenic and biophysical characterization has been developed. The first step toward this goal was cloning the porin gene from a *Neisseria*. Using a technique originally described by Feavers, *et al.* (Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629 (1992)), the DNA sequence of the mature porin protein from a class 3, serotype 15 porin was amplified using the chromosome of meningococcal strain 8765 as a template for the PCR reaction. Appropriate endonuclease restriction sites had been synthesized onto the ends of the oligonucleotide primers, such that when cleaved, the amplified mature porin sequence could be directly ligated and cloned into the chosen expression plasmid. After 30 cycles, the PCR products shown in Figure 2 were obtained. The major product migrated between 900bp and 1000bp which was in accord with the previous study (Feavers, I.M., *et al.*, *Infect. Immun.* 60:3620-3629 (1992)). However, a higher molecular weight product was not seen, even though the PCR was conducted under low annealing stringencies (40°C; 50 mM KCl).

To be able to produce large amounts of the cloned porin protein, the tightly controlled expression system of Studier, *et al.* (Studier and Moffatt, *J. Mol. Biol.* 189:113-130 (1986)) was employed, which is commercially available through Novagen Inc. The amplified PCR product was cloned into the *Bam*HI-*Xho*I site of plasmid pET-17b. This strategy places the DNA sequence for the mature porin protein in frame directly behind the T7 promoter, the DNA sequence encoding for the 9 amino acid leader sequence and 11 amino acids of the mature ϕ 10 protein. The Studier *E. coli* strain BL21 lysogenic for the DE3 lambda derivative (Studier and

- 31 -

Moffatt, *J. Mol. Biol.* 189:113-130 (1986)) was selected as the expression host for the pET-17b plasmid containing the porin gene. But because it was thought that the OmpA protein, originating from the *E. coli* expression host, might tend to co-purify with the expressed meningococcal porin protein, a modification of this strain was made by P1 transduction which eliminated the *ompA* gene from this strain. Thus, after restriction endonuclease digestion of both the PCR product and the pET-17b vector and ligation, the product was transformed into BL21(DE3)- Δ *ompA* and transformants selected for ampicillin and tetracycline resistance. Of the numerous colonies observed on the selection plate, 10 were picked for further characterization. All ten expressed large amounts of a protein, which migrated at the approximate molecular weight of the PorB protein, when grown to log phase and induced with IPTG. The whole cell lysate of one such culture is shown in Figure 3a. The western blot analysis with the 4D11 monoclonal antibody further suggested that the protein being expressed was the PorB protein (Figure 3b). As opposed to other studies, when neisserial porins have been cloned and expressed in *E. coli*, the host bacterial cells showed no signs of any toxic or lethal effects even after the addition of the IPTG. The *E. coli* cells appeared viable and could be recultured at any time throughout the expression phase.

Nucleotide sequence analysis: The amount of PorB expressed in these experiments was significantly greater than that previously observed and there appeared to be no adverse effects of this expression on the host *E. coli*. To be certain that no PCR artifacts had been introduced into the meningococcal porin gene to allow for such high expression, the entire ϕ 10 porin fusion was sequenced by double stranded primer extension from the plasmid. The results are shown in Figure 4. The nucleotide sequence was identical with another meningococcal serotype 15 *PorB* gene sequence previously reported by Heckels, *et al.* (Ward, M.J., *et al.*, *FEMS*

- 32 -

Microbiol. Lett. 73:283-289 (1992)) with two exceptions which are shown. These two nucleotide differences each occur in the third position of the codon and would not alter the amino acid sequence of the expressed protein. Thus, from the nucleotide sequence, there did not appear to be
5 any PCR artifact or mutation which might account for the high protein expression and lack of toxicity within the *E. coli*. Furthermore, this data would suggest that a true PorB protein was being produced.

Purification of the expressed porB gene product: The PorB protein expressed in the *E. coli* was insoluble in TEN buffer which suggested that
10 when expressed, the PorB protein formed into inclusion bodies. However, washing of the insoluble PorB protein with TEN buffer removed most of the contaminating *E. coli* proteins. The PorB protein could then be solubilized in freshly prepared 8M urea and diluted into the Zwittergent 3,14 detergent. The final purification was accomplished, using a Sephacryl
15 S-300 molecular sieve column which not only removed the urea but also the remaining contaminating proteins. The majority of the PorB protein eluted from the column having the apparent molecular weight of trimers much like the wild type PorB. The comparative elution patterns of both the wild type and the PorB expressed in the *E. coli* are shown in Figure 5. It is
20 important to note that when the PorB protein concentration in the 8 M urea was in excess of 10 mg/ml prior to dilution into the Zwittergent detergent, the relative amounts of PorB protein found as trimers decreased and appeared as aggregates eluting at the void volume. However, at protein concentrations below 10 mg/ml in the urea buffer, the majority of the PorB
25 eluted in the exact same fraction as did the wild type PorB. It was also determined using a T7-Tag monoclonal antibody and western blot analysis that the 11 amino acids of the mature T7 capsid protein were retained as the amino terminus. The total yield of the meningococcal porin protein from one liter of *E. coli* was approximately 50 mg.

- 33 -

Inhibition ELISA Assays. In order to determine if the purified trimeric recombinant PorB had a similar antigenic conformation as compared to the PorB produced in the wild type meningococcal strain 8765, the sera from six patients which had been vaccinated with the wild type meningococcal Type 15 PorB protein were used in inhibition ELISA assays. In the inhibition assay, antibodies reactive to the native PorB were competitively inhibited with various amounts of either the purified recombinant PorB or the homologous purified wild type PorB. The results of the inhibition with the homologous purified PorB of each of the six human sera and the mean inhibition of these sera are shown in Figure 6. The corresponding inhibition of these sera with the purified recombinant PorB is seen in Figure 6b. A comparison of the mean inhibition from Figure 6 and 7 are plotted in Figure 8. These data would suggest that the antibodies contained in the sera of these six patients found similar epitopes on both the homologous purified wild type PorB and the purified recombinant PorB. This gave further evidence that the recombinant PorB had regained most if not all of the native conformation found in the wild type PorB.

Example 2. Cloning of the Class 2 Porin from Group B Neisseria Meningitidis strain BNCV M986

Genomic DNA was isolated from approximately 0.5g of Group B *Neisseria meningitidis* strain BNCV M986 (serotype 2a) using previously described methods (Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press (1989)). This DNA then served as the template for two class 2 porin specific oligonucleotides in a standard PCR reaction. These oligonucleotides were designed to be complementary to the 5' and 3' flanking regions of the class 2 porin and to contain *EcoRI* restriction sites

- 34 -

to facilitate the cloning of the fragment. The sequences of the oligonucleotides were as follows: (SEQ ID NO. 16)

5' AGC GGC TTG GAA TTC CCG GCT GGC TTA AAT TTC 3' (SEQ ID NO. 17) and

5' CAA ACG AAT GAA TTC AAA TAA AAA AGC CTG 3'.

The polymerase chain reaction was then utilized to obtain the class 2 porin.

The reaction conditions were as follows: BNCV M986 genomic DNA 200ng, the two oligonucleotide primers described above at 1 μ M of each,

200 μ M of each dNTP, PCR reaction buffer (10 mM Tris HCl, 50 mM KCl, pH 8.3), 1.5 mM MgCl₂, and 2.5 units of *Taq* polymerase, made up

to 100 μ l with distilled H₂O. This reaction mixture was then subjected to

25 cycles of 95°C for 1 min, 50°C for 2 min and 72°C for 1.5 min. At

the end of the cycling period, the reaction mixture was loaded on a 1% agarose gel and the material was electrophoresed for 2h after which the

band at 1.3 kb was removed and the DNA recovered using the Gene Clean kit (Bio 101). This DNA was then digested with *Eco*RI, repurified and

ligated to *Eco*RI digested pUC19 using T₄ DNA ligase. The ligation mixture was used to transform competent *E. coli* DH5 α . Recombinant

plasmids were selected and sequenced. The insert was found to have a

DNA sequence consistent with that of a class 2 porin. See, Murakami, K. *et al.*, *Infect. Immun.* 57:2318-2323 (1989).

The plasmid pET-17b (Novagen) was used to express the class 2 porin. As described below, two plasmids were constructed that yielded two

different proteins. One plasmid was designed to produce a mature class 2

porin while the other was designed to yield a class 2 porin fused to 20 amino acids from the T7 gene ϕ 10 capsid protein.

- 35 -

Construction of the mature class 2 porin

The mature class 2 porin was constructed by amplifying the pUC19-class 2 porin construct using the oligonucleotides (SEQ ID NO. 18) 5' CCT GTT GCA GCA CAT ATG GAC GTT ACC TTG TAC GGT ACA ATT AAA GC 3' and (SEQ ID NO. 19) 5' CGA CAG GCT TTT TCT CGA GAC CAA TCT TTT CAG 3'. This strategy allowed the cloning of the amplified class 2 porin into the *Nde*I and *Xho*I sites of the plasmid pET-17b thus producing a mature class 2 porin. Standard PCR was conducted using the pUC19-class 2 as the template and the two oligonucleotides described above. This PCR reaction yielded a 1.1kb product when analyzed on a 1.0% agarose gel. The DNA obtained from the PCR reaction was gel purified and digested with the restriction enzymes *Nde*I and *Xho*I. The 1.1kb DNA produced was again gel purified and ligated to *Nde*I and *Xho*I digested pET-17b using T₄ DNA ligase. This ligation mixture was then used to transform competent *E. coli* DH5 α . Colonies that contained the 1.1kb insert were chosen for further analysis. The DNA from the DH5 α clones was analyzed by restriction mapping and the cloning junctions of the chosen plasmids were sequenced. After this analysis, the DNA obtained from the DH5 α clones was used to transform *E. coli* BL21(DE3)- $\Delta ompA$. The transformants were selected to LB-agar containing 100 μ g/ml of carbenicillin. Several transformants were screened for their ability to make the class 2 porin protein. This was done by growing the clones in LB liquid medium containing 100 μ g/ml of carbenicillin and 0.4% glucose at 30°C to OD₆₀₀ = 0.6 then inducing the cultures with IPTG (0.4 mM). The cells were then disrupted and the cell extract was analyzed by SDS-PAGE.

- 36 -

Construction of the fusion class 2 porin

The fusion class 2 porin was constructed by amplifying the pUC19-class 2 porin construct using the oligonucleotides (SEQ ID NO. 20) 5' CCT GTT GCA GCG GAT CCA GAC GTT ACC TTG TAC GGT ACA ATT AAA GC 3' and (SEQ ID NO. 21) 5' CGA CAG GCT TTT TCT CGA GAC CAA TCT TTT CAG 3'. This strategy allowed the cloning of the amplified class 2 porin into the *Bam*HI and *Xho*I sites of the plasmid pET-17b thus producing a fusion class 2 porin containing an additional 22 amino acids at the N-terminus derived from the T7 ϕ 10 capsid protein contained in the plasmid. Standard PCR was conducted using the pUC19-class 2 as the template and the two oligonucleotides described above. The PCR reaction yielded a 1.1kb product when analyzed on a 1.0% agarose gel. The DNA obtained from the PCR reaction was gel purified and digested with the reaction enzymes *Bam*HI and *Xho*I. The 1.1kb product produced was again gel purified and ligated to *Bam*HI and *Xho*I digested pET-17b using T₄ DNA ligase. This ligation mixture was then used to transform competent *E. coli* DH5 α . Colonies that contained the 1.1kb insert were chosen for further analysis. The DNA from the DH5 α clones was analyzed by restriction enzyme mapping and the cloning junctions of the chosen plasmids were sequenced. After this analysis, the DNA obtained from the DH5 α clones was used to transform *E. coli* BL21(DE3)- $\Delta ompA$. The transformants were selected on LB-agar containing 100 μ g/ml of carbenicillin. Several transformants were screened for their ability to make the class 2 porin protein. This was done by growing the clones in LB liquid medium containing 100 μ g/ml of carbenicillin and 0.4% glucose at 30°C to OD₆₀₀ = 0.6 then inducing the cultures with IPTG (0.4 mM). The cells were then disrupted and the cell extract was analyzed by SDS-PAGE.

- 37 -

Example 3. Cloning and Expression of the Mature class 3 porin from Group B *Neisseria meningitidis* strain 8765 in *E. coli*

Genomic DNA was isolated from approximately 0.5 g of Group B *Neisseria meningitidis* strain 8765 using the method described above (Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press (1989)). This DNA then served as the template for two class 3 porin specific oligonucleotides in a standard PCR reaction.

The mature class 3 porin was constructed by amplifying the genomic DNA from 8765 using the oligonucleotides: (SEQ ID NO. 22) 5' GTT GCA GCA CAT ATG GAC GTT ACC CTG TAC GGC ACC 3' (SEQ ID NO. 23) and 5' GGG GGG ATG GAT CCA GAT TAG AAT TTG TGG CGC AGA CCG ACA CC 3'. This strategy allowed the cloning of the amplified class 3 porin into the *Nde*I and *Bam*H sites of the plasmid pET-24a(+), thus producing a mature class 3 porin. Standard PCR was conducted using the genomic DNA isolated from 8765 as the template and the two oligonucleotides described above.

The reaction conditions were as follows: 8765 genomic DNA 200 ng, the two oligonucleotide primers described above at 1 μ M of each, 200 μ M of each dNTP, PCR reaction buffer (10 mM Tris HCl, 50 mM KCl, pH 8.3), 1.5 mM MgCl₂, and 2.5 units of *Taq* polymerase, and made up to 100 μ l with distilled water. This reaction mixture was then subjected to 25 cycles of 95°C for 1 min, 50°C for 2 min and 72°C for 1.5 min.

This PCR reaction yielded about 930 bp of product, as analyzed on a 1% agarose gel. The DNA obtained from the PCR reaction was gel purified and digested with the restriction enzymes *Nde*I and *Bam*HI. The 930 bp product was again gel purified and ligated to *Nde*I and *Bam*HI digested pET-24a(+) using T4 ligase. This ligation mixture was then used to transform competent *E. coli* DH5 α . Colonies that contained the 930 bp

- 38 -

insert were chosen for further analysis. The DNA from the *E. coli* DH5 α clones was analyzed by restriction enzyme mapping and cloning junctions of the chosen plasmids were sequenced. After this analysis, the DNA obtained from the *E. coli* DH5 α clones was used to transform *E. coli* BL21(DE3)- $\Delta ompA$. The transformants were selected on LB-agar containing 50 μ g/ml of kanamycin. Several transformants were screened for their ability to make the class 3 porin protein. This was done by growing the clones in LB liquid medium containing 50 μ g/ml of kanamycin and 0.4% of glucose at 30°C to OD₆₀₀ = 0.6 then inducing the cultures with IPTG (1 mM). The cells were then disrupted and the cell extract was analyzed by SDS-PAGE.

Example 4. Purification and refolding of recombinant class 2 porin

E. coli strain BL21(DE3) $\Delta ompA$ [pNV-5] is grown to mid-log phase (OD = 0.6 at 600 nm) in Luria broth at 30°C. IPTG is then added (0.4 mM final) and the cells grown an additional two hours at 37°C. The cells were then harvested and washed with several volumes of TEN buffer (50 mM Tris-HCl, 0.2 M NaCl, 10 mM EDTA, pH = 8.0) and the cell paste stored frozen at -75°C.

For purification preweighed cells are thawed and suspended in TEN buffer at a 1:15 ratio (g/v). The suspension is passed through a Stansted cell disrupter (Stansted fluid power Ltd.) twice at 8,000 psi. The resultant solution is then centrifuged at 13,000 rpm for 20 min and the supernatant discarded. The pellet is then twice suspended in TEN buffer containing 0.5% deoxycholate and the supernatants discarded. The pellet is then suspended in TEN buffer containing 8 M deionized urea (electrophoresis grade) and 0.1 mM PMSF (3 g/10ml). The suspension is sonicated for 10 min or until an even suspension is achieved. 10 ml of a 10% aqueous

- 39 -

solution of 3,14-zwittergen (Calbiochem) is added and the solution thoroughly mixed. The solution is again sonicated for 10 min. Any residual insoluble material is removed by centrifugation. The protein concentration is determined and the protein concentration adjusted to 2 mg/ml with 8 M urea-10% zwittergen buffer (1:1 ratio).

This mixture is then applied to a 2.6 x 100 cm column of Sephacryl S-300 equilibrated in 100 mM Tris-HCl, 1 M NaCl, 10 mM EDTA, 20 mM CaCl₂, 0.05% 3,14-zwittergen, 0.02% sodium azide, pH = 8.0. The flow rate is maintained at 1 ml/min. Fractions of 10 ml are collected. The porin refolds into trimer during the gel filtration. The OD = 280 nm of each fraction is measured and those fractions containing protein are subjected to SDS gel electrophoresis assay for porin. Those fractions containing porin are pooled. The pooled fractions are either dialyzed or diluted 1:10 in 50 mM Tris HCl pH = 8.0, 0.05% 3,14-zwittergen, 5 mM EDTA, 0.1 M NaCl. The resulting solution is then applied to a 2.6 x 10 cm Q sepharose high performance column (Pharmacia) equilibrated in the same buffer. The porin is eluted with a linear gradient of 0.1 to 1 M NaCl.

Example 5. Purification and refolding of recombinant class 3 porin

E coli strain BL21 (DE3) $\Delta ompA$ containing the porB-pET-17b plasmid is grown to mid-log phase (OD = 0.6 at 600 nm) in Luria broth at 30°C. IPTG is then added (0.4 mM final) and the cells grown an additional two hours at 37°C. The cells were then harvested and washed with several volumes of TEN buffer (50 mM Tris-HCl, 0.2 M NaCl, 10 mM EDTA, pH = 8.0) and the cell paste stored frozen at -75°C.

For purification about 3 grams of cells are thawed and suspended in 9 ml of TEN buffer. Lysozyme is added (Sigma, 0.25 mg/ml)

- 40 -

deoxycholate (Sigma, 1.3 mg/ml) plus PMSF (Sigma, $\mu\text{g/ml}$) and the mixture gently shaken for one hour at room temperature. During this time, the cells lyse and the released DNA causes the solution to become very viscous. DNase is then added (Sigma, 2 $\mu\text{g/ml}$) and the solution again mixed for one hour at room temperature. The mixture is then centrifuged at 15K rpm in a S-600 rotor for 30 minutes and the supernatant discarded. The pellet is then twice suspended in 10 ml of TEN buffer and the supernatants discarded. The pellet is then suspended in 10 ml of 8 M urea (Pierce) in TEN buffer. The mixture is gently stirred to break up any clumps. The suspension is sonicated for 20 minutes or until an even suspension is achieved. 10 ml of a 10% aqueous solution of 3,14-zwittergen (Calbiochem) is added and the solution thoroughly mixed. The solution is again sonicated for 10 minutes. Any residual insoluble material is removed by centrifugation. The protein concentration is determined and the protein concentration adjusted to 2 mg/ml with 8 M urea-10% zwittergen buffer (1:1 ratio).

This mixture is then applied to a 180 x 2.5 cm column of Sephacryl S-300 (Pharmacia) equilibrated in 100 mM Tris-HCl, 1 M NaCl, 10 mM EDTA, 20 mM CaCl_2 , 0.05% 3,14-zwittergen, pH = 8.0. The flow rate is maintained at 1 ml/min. Fractions of 10 ml are collected. The porin refolds into trimer during the gel filtration. The $\text{OD}_{280 \text{ nm}}$ of each fraction is measured and those fractions containing protein are subjected to SDS gel electrophoresis assay for porin. Those fractions containing porin are pooled.

The pooled fractions are dialyzed and concentrated 4-6 fold using Amicon concentrator with a PM 10 membrane against buffer containing 100 mM Tris-HCl, 0.1 M NaCl, 10 mM EDTA, 0.05% 3,14-zwittergen, pH = 8.0. Alternatively, the pooled fractions are precipitated with 80% ethanol and resuspended with the above-mentioned buffer. Six to 10 mg

- 41 -

of the material is then applied to a monoQ 10/10 column (Pharmacia) equilibrated in the same buffer. The porin is eluted from a shallow 0.1 to 0.6 M NaCl gradient with a 1.2% increase per min over a 50 min period. The Flow rate is 1 ml/min. The peak containing porin is collected and
5 dialyzed against TEN buffer and 0.05% 3,14-zwittergen. The porin may be purified further by another S-300 chromatography.

Example 6. Purification and chemical modification of the polysaccharides

The capsular polysaccharide from both group B *Neisseria meningitidis* and *E. coli* K1 consists of $\alpha(2\rightarrow8)$ polysialic acid (commonly referred to as GBMP or K1 polysaccharide). High molecular weight polysaccharide isolated from growth medium by precipitation (*see*, Frasch, C.E., "Production and Control of *Neisseria meningitidis* Vaccines" in *Bacterial Vaccines*, Alan R. Liss, Inc., pages 123-145 (1990)) was purified
10 and chemically modified before being coupled to the porin protein. The high molecular weight polysaccharide was partially depolymerized with 0.1 M acetic acid (7 mg polysaccharide/ml), pH = 6.0 to 6.5 (70°C, 3 hrs) to provide polysaccharide having an average molecular weight of 12,000-16,000. After purification by gel filtration column chromatography
15 (Superdex 200 prep grade, Pharmacia), the polysaccharide was N-deacetylated in the presence of NaBH₄ and then N-propionylated as described by Jennings *et al.* (*J. Immunol.* 137:1808 (1986)) to afford N-Pr GBMP. Treatment with NaIO₄ followed by gel filtration column
20 purification gave the oxidized N-Pr GBMP having an average molecular weight of 12,000 daltons.
25

- 42 -

Example 7. Coupling of oxidized N-Pr GBMP to the group B meningococcal class 3 porin protein (PP)

The oxidized N-Pr GBMP (9.5 mg) was added to purified class 3 porin protein (3.4 mg) dissolved in 0.21 ml of 0.2 M phosphate buffer pH 7.5 which also contained 10% octyl glucoside. After the polysaccharide was dissolved, sodium cyanoborohydride (7 mg) was added and the reaction solution was incubated at 37°C for 4 days. The reaction mixture was diluted with 0.15 M sodium chloride solution containing 0.01% thimerosal and separated by gel filtration column chromatography using Superdex 200 PG. The conjugate (N-Pr GBMP-PP) was obtained as single peak eluting near the void volume. Analysis of the conjugate solution for sialic acid and protein showed that the conjugate consists of 43% polysaccharide by weight. The porin protein was recovered in the conjugate in 44% yield and the polysaccharide in 12% yield. The protein recoveries in different experiments generally occur in the 50-80% range and those of the polysaccharide in the 9-13% range.

Example 8. Immunogenicity studies

The immunogenicities of the N-Pr GBMP-PP conjugate and those of the N-Pr GBMP-Tetanus toxoid (N-Pr GBMP-TT) conjugate which was prepared by a similar coupling procedure were assayed in 4-6 week old outbred Swiss Webster CFW female mice. The polysaccharide (2 µg)-conjugate was administered on days 1, 14 and 28, and the sera collected on day 38. The conjugates were administered as saline solutions, adsorbed on aluminum hydroxide, or admixed with stearyl tyrosine. The sera ELISA titers against the polysaccharide antigen and bactericidal titers against *N. meningitidis* group B are summarized in Table 1.

- 43 -

Having now fully described this invention, it will be understood to those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other perimeters without affecting the scope of the invention or any embodiment thereof.

5 All patents and publications cited herein are fully incorporated by reference herein in their entirety.

- 44 -

Table 1. ELISA and Bactericidal Titers of Group B Meningococcal Conjugate Vaccines (N-Pr GBMP-Protein)			
Vaccine	Adjuvant	ELISA Titer	Bactericidal Titer
N-Pr GBMP-TT	Saline	5,400	0
	Al(OH) ₃	13,000	0
	ST ¹	17,000	0
	CFA ²	40,000	800
N-Pr GBMP-PP	Saline	20,000	500
	Saline	22,000	150
	Saline	39,000	960
	Al(OH) ₃	93,000	200
	Al(OH) ₃	166,000	> 3,200
	Al(OH) ₃	130,000	1,200
	ST	53,000	1,000
	ST	29,000	1,700
	ST	72,000	1,500
N-Pr GBMP	Saline	> 100	0
	Al(OH) ₃	> 100	0
	ST	> 100	0
PP	Saline	> 100	0
	Al(OH) ₃	> 100	0
	ST	660	0

¹ST = Stearyl tyrosine.²CFA = Complete Freund's Adjuvant

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: The Rockefeller University
1230 York Avenue
New York, New York 10021
United States of America

North American Vaccine, Inc.
12103 Indian Creek Court
Beltsville, Maryland 20705
United States of America

INVENTORS: Blake, Milan B.
Tai, Joseph Y.
Qi, Huilin L.
Liang, Shu-Mei
Hronowski, Lucjan J.J.
Pullen, Jeffrey K.

(ii) TITLE OF INVENTION: Method for the High Level Expression,
Purification and Refolding of the Outer Membrane Group B
Porin Proteins from Neisseria Meningitidis

(iii) NUMBER OF SEQUENCES: 23

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Sterne, Kessler, Goldstein & Fox
(B) STREET: 1100 New York Ave., Suite 600
(C) CITY: Washington
(D) STATE: D.C.
(E) COUNTRY: USA
(F) ZIP: 20005-3934

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To be Assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) Application No.: US 08/096,182
(B) Filing Date: 23 July 1993

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Esmond, Robert W.
(B) REGISTRATION NUMBER: 32,893
(C) REFERENCE/DOCKET NUMBER: 1438.006PC00

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (202) 371-2600
(B) TELEFAX: (202) 371-2540

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 930 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: both

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..930

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TTG TAC GGT ACA ATT AAA GCA GGC GTA GAA ACT TCC CGC TCT GTA TTT	48
Leu Tyr Gly Thr Ile Lys Ala Gly Val Glu Thr Ser Arg Ser Val Phe	
1 5 10 15	
CAC CAG AAC GGC CAA GTT ACT GAA GTT ACA ACC GCT ACC GGC ATC GTT	96
His Gln Asn Gly Gln Val Thr Glu Val Thr Thr Ala Thr Gly Ile Val	
20 25 30	
GAT TTG GGT TCG AAA ATC GGC TTC AAA GGC CAA GAA GAC CTC GGT AAC	144
Asp Leu Gly Ser Lys Ile Gly Phe Lys Gly Gln Glu Asp Leu Gly Asn	
35 40 45	
GGC CTG AAA GCC ATT TGG CAG GTT GAG CAA AAA GCA TCT ATC GCC GGT	192
Gly Leu Lys Ala Ile Trp Gln Val Glu Gln Lys Ala Ser Ile Ala Gly	
50 55 60	
ACT GAC TCC GGT TGG GGC AAC CGC CAA TCC TTC ATC GGC TTG AAA GGC	240
Thr Asp Ser Gly Trp Gly Asn Arg Gln Ser Phe Ile Gly Leu Lys Gly	
65 70 75 80	
GGC TTC GGT AAA TTG CGC GTC GGT CGT TTG AAC AGC GTC CTG AAA GAC	288
Gly Phe Gly Lys Leu Arg Val Gly Arg Leu Asn Ser Val Leu Lys Asp	
85 90 95	
ACC GGC GAC ATC AAT CCT TGG GAT AGC AAA AGC GAC TAT TTG GGT GTA	336
Thr Gly Asp Ile Asn Pro Trp Asp Ser Lys Ser Asp Tyr Leu Gly Val	
100 105 110	
AAC AAA ATT GCC GAA CCC GAG GCA CGC CTC ATT TCC GTA CGC TAC GAT	384
Asn Lys Ile Ala Glu Pro Glu Ala Arg Leu Ile Ser Val Arg Tyr Asp	
115 120 125	
TCT CCC GAA TTT GCC GGC CTC AGC GGC AGC GTA CAA TAC GCG CTT AAC	432
Ser Pro Glu Phe Ala Gly Leu Ser Gly Ser Val Gln Tyr Ala Leu Asn	
130 135 140	
GAC AAT GCA GGC AGA CAT AAC AGC GAA TCT TAC CAC GCC GGC TTC AAC	480
Asp Asn Ala Gly Arg His Asn Ser Glu Ser Tyr His Ala Gly Phe Asn	
145 150 155 160	
TAC AAA AAC GGT GGC TTC TTC GTG CAA TAT GGC GGT GCC TAT AAA AGA	528
Tyr Lys Asn Gly Gly Phe Phe Val Gln Tyr Gly Gly Ala Tyr Lys Arg	
165 170 175	
CAT CAT CAA GTG CAA GAG GGC TTG AAT ATT GAG AAA TAC CAG ATT CAC	576
His His Gln Val Gln Glu Gly Leu Asn Ile Glu Lys Tyr Gln Ile His	
180 185 190	
CGT TTG GTC AGC GGT TAC GAC AAT GAT GCC CTG TAC GCT TCC GTA GCC	624
Arg Leu Val Ser Gly Tyr Asp Asn Asp Ala Leu Tyr Ala Ser Val Ala	
195 200 205	
GTA CAG CAA CAA GAC GCG AAA CTG ACT GAT GCT TCC AAT TCG CAC AAC	672
Val Gln Gln Gln Asp Ala Lys Leu Thr Asp Ala Ser Asn Ser His Asn	
210 215 220	
TCT CAA ACC GAA GTT GCC GCT ACC TTG GCA TAC CGC TTC GGC AAC GTA	720
Ser Gln Thr Glu Val Ala Ala Thr Leu Ala Tyr Arg Phe Gly Asn Val	
225 230 235 240	
ACG CCC CGA GTT TCT TAC GCC CAC GGC TTC AAA GGT TTG GTT GAT GAT	768
Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys Gly Leu Val Asp Asp	
245 250 255	
GCA GAC ATA GGC AAC GAA TAC GAC CAA GTG GTT GTC GGT GCG GAA TAC	816
Ala Asp Ile Gly Asn Glu Tyr Asp Gln Val Val Val Gly Ala Glu Tyr	
260 265 270	

47

GAC TTC TCC AAA CGC ACT TCT GCC TTG GTT TCT GCC GGT TGG TTG CAA	864
Asp Phe Ser Lys Arg Thr Ser Ala Leu Val Ser Ala Gly Trp Leu Gln	
275 280 285	
GAA GGC AAA GGC GAA AAC AAA TTC GTA GCG ACT GCC GGC GGT GTT GGT	912
Glu Gly Lys Gly Glu Asn Lys Phe Val Ala Thr Ala Gly Gly Val Gly	
290 295 300	
CTG CGT CAC AAA TTC TAA	930
Leu Arg His Lys Phe	
305 310	

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 309 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu Tyr Gly Thr Ile Lys Ala Gly Val Glu Thr Ser Arg Ser Val Phe	
1 5 10 15	
His Gln Asn Gly Gln Val Thr Glu Val Thr Thr Ala Thr Gly Ile Val	
20 25 30	
Asp Leu Gly Ser Lys Ile Gly Phe Lys Gly Gln Glu Asp Leu Gly Asn	
35 40 45	
Gly Leu Lys Ala Ile Trp Gln Val Glu Gln Lys Ala Ser Ile Ala Gly	
50 55 60	
Thr Asp Ser Gly Trp Gly Asn Arg Gln Ser Phe Ile Gly Leu Lys Gly	
65 70 75 80	
Gly Phe Gly Lys Leu Arg Val Gly Arg Leu Asn Ser Val Leu Lys Asp	
85 90 95	
Thr Gly Asp Ile Asn Pro Trp Asp Ser Lys Ser Asp Tyr Leu Gly Val	
100 105 110	
Asn Lys Ile Ala Glu Pro Glu Ala Arg Leu Ile Ser Val Arg Tyr Asp	
115 120 125	
Ser Pro Glu Phe Ala Gly Leu Ser Gly Ser Val Gln Tyr Ala Leu Asn	
130 135 140	
Asp Asn Ala Gly Arg His Asn Ser Glu Ser Tyr His Ala Gly Phe Asn	
145 150 155 160	
Tyr Lys Asn Gly Gly Phe Phe Val Gln Tyr Gly Gly Ala Tyr Lys Arg	
165 170 175	
His His Gln Val Gln Glu Gly Leu Asn Ile Glu Lys Tyr Gln Ile His	
180 185 190	
Arg Leu Val Ser Gly Tyr Asp Asn Asp Ala Leu Tyr Ala Ser Val Ala	
195 200 205	
Val Gln Gln Gln Asp Ala Lys Leu Thr Asp Ala Ser Asn Ser His Asn	
210 215 220	

48

Ser Gln Thr Glu Val Ala Ala Thr Leu Ala Tyr Arg Phe Gly Asn Val
 225 230 235 240

Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys Gly Leu Val Asp Asp
 245 250 255

Ala Asp Ile Gly Asn Glu Tyr Asp Gln Val Val Val Gly Ala Glu Tyr
 260 265 270

Asp Phe Ser Lys Arg Thr Ser Ala Leu Val Ser Ala Gly Trp Leu Gln
 275 280 285

Glu Gly Lys Gly Glu Asn Lys Phe Val Ala Thr Ala Gly Gly Val Gly
 290 295 300

Leu Arg His Lys Phe
 305

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1029 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..1029

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG GAC GTT ACC TTG TAC GGT ACA ATT AAA GCA GGC GTA GAA GTT TCT	48
Met Asp Val Thr Leu Tyr Gly Thr Ile Lys Ala Gly Val Glu Val Ser	
1 5 10 15	
CGC GTA AAA GAT GCT GGT ACA TAT AAA GCT CAA GGC GGA AAA TCT AAA	96
Arg Val Lys Asp Ala Gly Thr Tyr Lys Ala Gln Gly Gly Lys Ser Lys	
20 25 30	
ACT GCA ACC CAA ATT GCC GAC TTC GGT TCT AAA ATC GGT TTC AAA GGT	144
Thr Ala Thr Gln Ile Ala Asp Phe Gly Ser Lys Ile Gly Phe Lys Gly	
35 40 45	
CAA GAA GAC CTC GGC AAC GGC ATG AAA GCC ATT TGG CAG TTG GAA CAA	192
Gln Glu Asp Leu Gly Asn Gly Met Lys Ala Ile Trp Gln Leu Glu Gln	
50 55 60	
AAA GCC TCC ATC GCC GGC ACT AAC AGC GGC TGG GGT AAC CGC CAG TCC	240
Lys Ala Ser Ile Ala Gly Thr Asn Ser Gly Trp Gly Asn Arg Gln Ser	
65 70 75 80	
TTC ATC GGC TTG AAA GGC GGC TTC GGT ACC GTC CGC GCC GGT AAT CTG	288
Phe Ile Gly Leu Lys Gly Gly Phe Gly Thr Val Arg Ala Gly Asn Leu	
85 90 95	
AAC ACC GTA TTG AAA GAC AGC GGC GAC AAC GTC AAT GCA TGG GAA TCT	336
Asn Thr Val Leu Lys Asp Ser Gly Asp Asn Val Asn Ala Trp Glu Ser	
100 105 110	
GGT TCT AAC ACC GAA GAT GTA CTG GGA CTG GGT ACT ATC GGT CGT GTA	384
Gly Ser Asn Thr Glu Asp Val Leu Gly Leu Gly Thr Ile Gly Arg Val	
115 120 125	

49

GAA AGC CGT GAA ATC TCC GTA CGC TAC GAC TCT CCC GTA TTT GCA GGC Glu Ser Arg Glu Ile Ser Val Arg Tyr Asp Ser Pro Val Phe Ala Gly 130 135 140	432
TTC AGC GGC AGC GTA CAA TAC GTT CCG CGC GAT AAT GCG AAT GAT GTG Phe Ser Gly Ser Val Gln Tyr Val Pro Arg Asp Asn Ala Asn Asp Val 145 150 155 160	480
GAT AAA TAC AAA CAT ACG AAG TCC AGC CGT GAG TCT TAC CAC GCC GGT Asp Lys Tyr Lys His Thr Lys Ser Ser Arg Glu Ser Tyr His Ala Gly 165 170 175	528
CTG AAA TAC GAA AAT GCC GGT TTC TTC GGT CAA TAC GCA GGT TCT TTT Leu Lys Tyr Glu Asn Ala Gly Phe Phe Gly Gln Tyr Ala Gly Ser Phe 180 185 190	576
GCC AAA TAT GCT GAT TTG AAC ACT GAT GCA GAA CGT GTT GCA GTA AAT Ala Lys Tyr Ala Asp Leu Asn Thr Asp Ala Glu Arg Val Ala Val Asn 195 200 205	624
ACT GCA AAT GCC CAT CCT GTT AAG GAT TAC CAA GTA CAC CGC GTA GTT Thr Ala Asn Ala His Pro Val Lys Asp Tyr Gln Val His Arg Val Val 210 215 220	672
GCC GGT TAC GAT GCC AAT GAC CTG TAC GTT TCT GTT GCC GGT CAG TAT Ala Gly Tyr Asp Ala Asn Asp Leu Tyr Val Ser Val Ala Gly Gln Tyr 225 230 235 240	720
GAA GCT GCT AAA AAC AAC GAG GTT GGT TCT ACC AAG GGT AAA AAA CAC Glu Ala Ala Lys Asn Asn Glu Val Gly Ser Thr Lys Gly Lys Lys His 245 250 255	768
GAG CAA ACT CAA GTT GCC GCT ACT GCC GCT TAC CGT TTT GGC AAC GTA Glu Gln Thr Gln Val Ala Ala Thr Ala Ala Tyr Arg Phe Gly Asn Val 260 265 270	816
ACG CCT CGC GTT TCT TAC GCC CAC GGC TTC AAA GCT AAA GTG AAT GGC Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys Ala Lys Val Asn Gly 275 280 285	864
GTG AAA GAC GCA AAT TAC CAA TAC GAC CAA GTT ATC GTT GGT GCC GAC Val Lys Asp Ala Asn Tyr Gln Tyr Asp Gln Val Ile Val Gly Ala Asp 290 295 300	912
TAC GAC TTC TCC AAA CGC ACT TCC GCT CTG GTT TCT GCC GGT TGG TTG Tyr Asp Phe Ser Lys Arg Thr Ser Ala Leu Val Ser Ala Gly Trp Leu 305 310 315 320	960
AAA CAA GGT AAA GGC GCG GGA AAA GTC GAA CAA ACT GCC AGC ATG GTT Lys Gln Gly Lys Gly Ala Gly Lys Val Glu Gln Thr Ala Ser Met Val 325 330 335	1008
GGT CTG CGT CAC AAA TTC TAA Gly Leu Arg His Lys Phe 340	1029

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 342 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Asp Val Thr Leu Tyr Gly Thr Ile Lys Ala Gly Val Glu Val Ser
 1 5 10 15
 Arg Val Lys Asp Ala Gly Thr Tyr Lys Ala Gln Gly Gly Lys Ser Lys
 20 25 30
 Thr Ala Thr Gln Ile Ala Asp Phe Gly Ser Lys Ile Gly Phe Lys Gly
 35 40 45
 Gln Glu Asp Leu Gly Asn Gly Met Lys Ala Ile Trp Gln Leu Glu Gln
 50 55 60
 Lys Ala Ser Ile Ala Gly Thr Asn Ser Gly Trp Gly Asn Arg Gln Ser
 65 70 75 80
 Phe Ile Gly Leu Lys Gly Gly Phe Gly Thr Val Arg Ala Gly Asn Leu
 85 90 95
 Asn Thr Val Leu Lys Asp Ser Gly Asp Asn Val Asn Ala Trp Glu Ser
 100 105 110
 Gly Ser Asn Thr Glu Asp Val Leu Gly Leu Gly Thr Ile Gly Arg Val
 115 120 125
 Glu Ser Arg Glu Ile Ser Val Arg Tyr Asp Ser Pro Val Phe Ala Gly
 130 135 140
 Phe Ser Gly Ser Val Gln Tyr Val Pro Arg Asp Asn Ala Asn Asp Val
 145 150 155 160
 Asp Lys Tyr Lys His Thr Lys Ser Ser Arg Glu Ser Tyr His Ala Gly
 165 170 175
 Leu Lys Tyr Glu Asn Ala Gly Phe Phe Gly Gln Tyr Ala Gly Ser Phe
 180 185 190
 Ala Lys Tyr Ala Asp Leu Asn Thr Asp Ala Glu Arg Val Ala Val Asn
 195 200 205
 Thr Ala Asn Ala His Pro Val Lys Asp Tyr Gln Val His Arg Val Val
 210 215 220
 Ala Gly Tyr Asp Ala Asn Asp Leu Tyr Val Ser Val Ala Gly Gln Tyr
 225 230 235 240
 Glu Ala Ala Lys Asn Asn Glu Val Gly Ser Thr Lys Gly Lys Lys His
 245 250 255
 Glu Gln Thr Gln Val Ala Ala Thr Ala Ala Tyr Arg Phe Gly Asn Val
 260 265 270
 Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys Ala Lys Val Asn Gly
 275 280 285
 Val Lys Asp Ala Asn Tyr Gln Tyr Asp Gln Val Ile Val Gly Ala Asp
 290 295 300
 Tyr Asp Phe Ser Lys Arg Thr Ser Ala Leu Val Ser Ala Gly Trp Leu
 305 310 315 320
 Lys Gln Gly Lys Gly Ala Gly Lys Val Glu Gln Thr Ala Ser Met Val
 325 330 335
 Gly Leu Arg His Lys Phe
 340

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1092 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: both

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..1092

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT TCA AGC TTG	48
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu	
1 5 10 15	
GTA CCG AGC TCG GAT CCA GAC GTT ACC TTG TAC GGT ACA ATT AAA GCA	96
Val Pro Ser Ser Asp Pro Asp Val Thr Leu Tyr Gly Thr Ile Lys Ala	
20 25 30	
GGC GTA GAA GTT TCT CGC GTA AAA GAT GCT GGT ACA TAT AAA GCT CAA	144
Gly Val Glu Val Ser Arg Val Lys Asp Ala Gly Thr Tyr Lys Ala Gln	
35 40 45	
GGC GGA AAA TCT AAA ACT GCA ACC CAA ATT GCC GAC TTC GGT TCT AAA	192
Gly Gly Lys Ser Lys Thr Ala Thr Gln Ile Ala Asp Phe Gly Ser Lys	
50 55 60	
ATC GGT TTC AAA GGT CAA GAA GAC CTC GGC AAC GGC ATG AAA GCC ATT	240
Ile Gly Phe Lys Gly Gln Glu Asp Leu Gly Asn Gly Met Lys Ala Ile	
65 70 75 80	
TGG CAG TTG GAA CAA AAA GCC TCC ATC GCC GGC ACT AAC AGC GGC TGG	288
Trp Gln Leu Glu Lys Ala Ser Ile Ala Gly Thr Asn Ser Gly Trp	
85 90 95	
GGT AAC CGC CAG TCC TTC ATC GGC TTG AAA GGC GGC TTC GGT ACC GTC	336
Gly Asn Arg Gln Ser Phe Ile Gly Leu Lys Gly Gly Phe Gly Thr Val	
100 105 110	
CGC GCC GGT AAT CTG AAC ACC GTA TTG AAA GAC AGC GGC GAC AAC GTC	384
Arg Ala Gly Asn Leu Asn Thr Val Leu Lys Asp Ser Gly Asp Asn Val	
115 120 125	
AAT GCA TGG GAA TCT GGT TCT AAC ACC GAA GAT GTA CTG GGA CTG GGT	432
Asn Ala Trp Glu Ser Gly Ser Asn Thr Glu Asp Val Leu Gly Leu Gly	
130 135 140	
ACT ATC GGT CGT GTA GAA AGC CGT GAA ATC TCC GTA CGC TAC GAC TCT	480
Thr Ile Gly Arg Val Glu Ser Arg Glu Ile Ser Val Arg Tyr Asp Ser	
145 150 155 160	
CCC GTA TTT GCA GGC TTC AGC GGC AGC GTA CAA TAC GTT CCG CGC GAT	528
Pro Val Phe Ala Gly Phe Ser Gly Ser Val Gln Tyr Val Pro Arg Asp	
165 170 175	
AAT GCG AAT GAT GTG GAT AAA TAC AAA CAT ACG AAG TCC AGC CGT GAG	576
Asn Ala Asn Asp Val Asp Lys Tyr Lys His Thr Lys Ser Ser Arg Glu	
180 185 190	
TCT TAC CAC GCC GGT CTG AAA TAC GAA AAT GCC GGT TTC TTC GGT CAA	624
Ser Tyr His Ala Gly Leu Lys Tyr Glu Asn Ala Gly Phe Phe Gly Gln	
195 200 205	

52

TAC GCA GGT TCT TTT GCC AAA TAT GCT GAT TTG AAC ACT GAT GCA GAA Tyr Ala Gly Ser Phe Ala Lys Tyr Ala Asp Leu Asn Thr Asp Ala Glu 210 215 220	672
CGT GTT GCA GTA AAT ACT GCA AAT GCC CAT CCT GTT AAG GAT TAC CAA Arg Val Ala Val Asn Thr Ala Asn Ala His Pro Val Lys Asp Tyr Gln 225 230 235 240	720
GTA CAC CGC GTA GTT GCC GGT TAC GAT GCC AAT GAC CTG TAC GTT TCT Val His Arg Val Val Ala Gly Tyr Asp Ala Asn Asp Leu Tyr Val Ser 245 250 255	768
GTT GCC GGT CAG TAT GAA GCT GCT AAA AAC AAC GAG GTT GGT TCT ACC Val Ala Gly Gln Tyr Glu Ala Ala Lys Asn Asn Glu Val Gly Ser Thr 260 265 270	816
AAG GGT AAA AAA CAC GAG CAA ACT CAA GTT GCC GCT ACT GCC GCT TAC Lys Gly Lys Lys His Glu Gln Thr Gln Val Ala Ala Thr Ala Ala Tyr 275 280 285	864
CGT TTT GGC AAC GTA ACG CCT CGC GTT TCT TAC GCC CAC GGC TTC AAA Arg Phe Gly Asn Val Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys 290 295 300	912
GCT AAA GTG AAT GGC GTG AAA GAC GCA AAT TAC CAA TAC GAC CAA GTT Ala Lys Val Asn Gly Val Lys Asp Ala Asn Tyr Gln Tyr Asp Gln Val 305 310 315 320	960
ATC GTT GGT GCC GAC TAC GAC TTC TCC AAA CGC ACT TCC GCT CTG GTT Ile Val Gly Ala Asp Tyr Asp Phe Ser Lys Arg Thr Ser Ala Leu Val 325 330 335	1008
TCT GCC GGT TGG TTG AAA CAA GGT AAA GGC GCG GGA AAA GTC GAA CAA Ser Ala Gly Trp Leu Lys Gln Gly Lys Gly Ala Gly Lys Val Glu Gln 340 345 350	1056
ACT GCC AGC ATG GTT GGT CTG CGT CAC AAA TTC TAA Thr Ala Ser Met Val Gly Leu Arg His Lys Phe 355 360	1092

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 363 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu 1 5 10 15
Val Pro Ser Ser Asp Pro Asp Val Thr Leu Tyr Gly Thr Ile Lys Ala 20 25 30
Gly Val Glu Val Ser Arg Val Lys Asp Ala Gly Thr Tyr Lys Ala Gln 35 40 45
Gly Gly Lys Ser Lys Thr Ala Thr Gln Ile Ala Asp Phe Gly Ser Lys 50 55 60
Ile Gly Phe Lys Gly Gln Glu Asp Leu Gly Asn Gly Met Lys Ala Ile 65 70 75 80

53

Trp	Gln	Leu	Glu	Gln	Lys	Ala	Ser	Ile	Ala	Gly	Thr	Asn	Ser	Gly	Trp
				85					90					95	
Gly	Asn	Arg	Gln	Ser	Phe	Ile	Gly	Leu	Lys	Gly	Gly	Phe	Gly	Thr	Val
			100					105					110		
Arg	Ala	Gly	Asn	Leu	Asn	Thr	Val	Leu	Lys	Asp	Ser	Gly	Asp	Asn	Val
		115					120					125			
Asn	Ala	Trp	Glu	Ser	Gly	Ser	Asn	Thr	Glu	Asp	Val	Leu	Gly	Leu	Gly
		130				135					140				
Thr	Ile	Gly	Arg	Val	Glu	Ser	Arg	Glu	Ile	Ser	Val	Arg	Tyr	Asp	Ser
145					150					155					160
Pro	Val	Phe	Ala	Gly	Phe	Ser	Gly	Ser	Val	Gln	Tyr	Val	Pro	Arg	Asp
				165					170					175	
Asn	Ala	Asn	Asp	Val	Asp	Lys	Tyr	Lys	His	Thr	Lys	Ser	Ser	Arg	Glu
			180					185					190		
Ser	Tyr	His	Ala	Gly	Leu	Lys	Tyr	Glu	Asn	Ala	Gly	Phe	Phe	Gly	Gln
		195					200					205			
Tyr	Ala	Gly	Ser	Phe	Ala	Lys	Tyr	Ala	Asp	Leu	Asn	Thr	Asp	Ala	Glu
	210					215					220				
Arg	Val	Ala	Val	Asn	Thr	Ala	Asn	Ala	His	Pro	Val	Lys	Asp	Tyr	Gln
225					230					235					240
Val	His	Arg	Val	Val	Ala	Gly	Tyr	Asp	Ala	Asn	Asp	Leu	Tyr	Val	Ser
				245					250					255	
Val	Ala	Gly	Gln	Tyr	Glu	Ala	Ala	Lys	Asn	Asn	Glu	Val	Gly	Ser	Thr
			260					265					270		
Lys	Gly	Lys	Lys	His	Glu	Gln	Thr	Gln	Val	Ala	Ala	Thr	Ala	Ala	Tyr
		275					280					285			
Arg	Phe	Gly	Asn	Val	Thr	Pro	Arg	Val	Ser	Tyr	Ala	His	Gly	Phe	Lys
	290					295					300				
Ala	Lys	Val	Asn	Gly	Val	Lys	Asp	Ala	Asn	Tyr	Gln	Tyr	Asp	Gln	Val
305					310					315				320	
Ile	Val	Gly	Ala	Asp	Tyr	Asp	Phe	Ser	Lys	Arg	Thr	Ser	Ala	Leu	Val
				325					330					335	
Ser	Ala	Gly	Trp	Leu	Lys	Gln	Gly	Lys	Gly	Ala	Gly	Lys	Val	Glu	Gln
			340					345					350		
Thr	Ala	Ser	Met	Val	Gly	Leu	Arg	His	Lys	Phe					
		355					360								

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- SEQUENCE CHARACTERISTICS
- (A) LENGTH: 187 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 101..187

54

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

AGATCTCGAT CCCGCGAAAT TAATACGACT CACTATAGGG AGACCACAAC GGTTCCTC      60
TAGAAATAAT TTTGTTTAAC TTAAAGAAGG AGATATACAT ATG GCT AGC ATG ACT      115
                                         Met Ala Ser Met Thr
                                         1           5

GGT GGA CAG CAA ATG GGT CGG GAT TCA AGC TTG GTA CCG AGC TCG GAT      163
Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu Val Pro Ser Ser Asp
              10              15              20

CTG CAG GTT ACC TTG TAC GGT ACA      187
Leu Gln Val Thr Leu Tyr Gly Thr
              25

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu
 1           5           10           15
Val Pro Ser Ser Asp Leu Gln Val Thr Leu Tyr Gly Thr
              20              25

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 54 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

GTT GGT CTG CGT CAC AAA TTC TAACTCGAGC AGATCCGGCT GCTAACAAAG      51
Val Gly Leu Arg His Lys Phe
 1           5

CCC      54

```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

Val Gly Leu Arg His Lys Phe
 1           5

```


(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGGTAGATC TGCAGGTTAC CTTGTACGGT ACAATTAAAG CAGGCGT

47

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGGGGGGTGA CCCTCGAGTT AGAATTTGTG ACGCAGACCA AC

42

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TCAAGCTTGG TACCGAGCTC

20

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TTTGTTAGCA GCCGGATCTG

20

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CTCAAGACCC GTTTAGAGGC C

21

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
AGCGGCTTGG AATTCCCGGC TGGCTTAAAT TTC 33
- (2) INFORMATION FOR SEQ ID NO:17:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
CAAACGAATG AATTCAAATA AAAAAGCCTG 30
- (2) INFORMATION FOR SEQ ID NO:18:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
CCTGTTGCAG CACATATGGA CGTTACCTTG TACGGTACAA TTAAAGC 47
- (2) INFORMATION FOR SEQ ID NO:19:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
CGACAGGCTT TTTCTCGAGA CCAATCTTTT CAG 33
- (2) INFORMATION FOR SEQ ID NO:20:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
CCTGTTGCAG CGGATCCAGA CGTTACCTTG TACGGTACAA TTAAAGC 47
- (2) INFORMATION FOR SEQ ID NO:21:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
CGACAGGCTT TTTCTCGAGA CCAATCTTTT CAG 33
- (2) INFORMATION FOR SEQ ID NO:22:

57

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GTTGCAGCAC ATATGGACGT TACCCTGTAC GGCACC

36

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 44 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGGGGGATGG ATCCAGATTA GAATTTGTGG CGCAGACCGA CACC

44

- 58 -

What Is Claimed Is:

1. A method for the high level expression of the outer membrane meningococcal group B porin protein or fusion protein thereof in *E. coli*,
5 comprising:

(a) transforming into an *E. coli* strain a vector comprising a selectable marker and a gene coding for a protein selected from the group consisting of:

(i) a mature porin protein, and

(ii) a fusion protein which is a mature porin protein fused to amino acids 1 to 22 of the T7 gene $\phi 10$ capsid protein;

wherein said gene is operably linked to the T7 promoter;

(b) growing the transformed *E. coli* in a culture medium containing a selection agent, and

(c) inducing expression of said protein to give *E. coli* containing said protein;

wherein the protein so expressed comprises more than about 2% of the total protein expressed in said *E. coli*.

2. The method according to claim 1, wherein said protein is the mature group B class 2 porin protein.

3. The method according to claim 1, wherein said protein is the mature group B class 3 porin protein.

4. The method according to claim 1, wherein said protein comprises more than about 30% of the total proteins expressed in said *E. coli*.

5. The method of claim 1, wherein said vector is selected from the group consisting of pET-17b, pET-11a, pET-24a-d(+) and pET-9a.

- 59 -

6. A method of purifying the outer membrane meningococcal group B porin protein or fusion protein thereof obtained according to the method of claim 1 comprising:

- (d) lysing said *E. coli* obtained in step (c) to release said protein as insoluble inclusion bodies;
- (e) washing said insoluble inclusion bodies obtained in step (c) with a buffer to remove contaminating *E. coli* cellular proteins;
- (f) suspending and dissolving said inclusion bodies obtained in step (e) in an aqueous solution of a denaturant;
- (g) diluting the solution obtained in step (f) with a detergent; and
- (h) purifying said protein by gel filtration and ion exchange chromatography.

7. The method of claim 6, wherein the diluted solution obtained in step (g) has a concentration of less than 10 mg protein/ml.

8. A method of refolding the outer membrane meningococcal group B porin protein or fusion protein thereof obtained according to the method of claim 1 comprising:

- (d) lysing said *E. coli* obtained in step (c) to release said protein as insoluble inclusion bodies;
- (e) washing said insoluble inclusion bodies obtained in step (c) with a buffer to remove contaminating *E. coli* cellular proteins;
- (f) suspending and dissolving said inclusion bodies obtained in step (e) in an aqueous solution of a denaturant;
- (g) diluting the solution obtained in step (f) with a detergent; and
- (h) passing said diluted solution obtained in step (g) through a gel filtration column;

whereby folded, trimeric protein is obtained.

- 60 -

9. The method of claim 8, wherein the diluted solution obtained in step (g) has a concentration of less than 10 mg protein/ml.

5 10. A substantially pure outer membrane meningococcal group B porin protein or fusion protein thereof produced according to the method of claim 6.

11. The substantially pure protein of claim 10, which is the mature group B class 2 porin protein.

10 12. The substantially pure protein of claim 10, which is the mature group B class 3 porin protein.

15 13. A substantially pure refolded outer membrane meningococcal group B porin protein or fusion protein thereof produced according to the method of claim 8.

20 14. A vaccine comprising the outer membrane meningococcal group B porin protein or fusion protein thereof of claim 10 or 13 together with a pharmaceutically acceptable diluent, carrier, or excipient, wherein said protein is present in an amount effective to elicit protective antibodies in an animal to *Neisseria meningitidis*.

25 15. The vaccine according to claim 14, wherein said protein is conjugated to a *Neisseria meningitidis* capsular polysaccharide.

16. A method of obtaining a meningococcal group B porin protein or fusion protein-polysaccharide conjugate comprising:

30 (c) obtaining the refolded protein according to the method of claim 8;

- 61 -

- (d) obtaining a *Neisseria meningitidis* capsular polysaccharide; and
- (e) conjugating the protein (a) to the polysaccharide of (b).

17. The method of claim 16, wherein said protein has the amino acid sequence depicted in Figure 4.

18. A method of preventing bacterial meningitis in an animal comprising administering to said animal the meningococcal group B porin protein or fusion protein thereof produced according to claim 8 in an amount effective to prevent bacterial meningitis.

19. An *E. coli* strain BL21 (DE3) $\Delta ompA$ host cell that contains a vector which comprises a DNA molecule coding for a meningococcal group B porin protein or fusion protein thereof operably linked to the T7 promotor of said vector.

20. The *E. coli* strain of claim 19, wherein said DNA molecule codes for the mature meningococcal group B class 2 porin protein.

21. The *E. coli* strain of claim 19, wherein said DNA molecule codes for the mature meningococcal group B class 3 porin protein.

22. The *E. coli* strain of claim 19, wherein said DNA molecule codes for a fusion protein having the amino acid sequence depicted in figure 4.

23. The *E. coli* strain of claim 19, wherein said vector is pET-17b.

24. *E. coli* strain BL21(DE3) $\Delta ompA$.

1/17




FIG.1

2/17




FIG. 2




FIG. 3A




FIG. 3B

4/17

TTG TAC GGT ^C ACA ^C ATT AAA GCA GGC GTA GAA ACT TCC CGC TCT GTA TTT	48
Leu Tyr Gly Thr Ile Lys Ala Gly Val Glu Thr Ser Arg Ser Val Phe	
1 5 10 15	
CAC CAG AAC GGC CAA GTT ACT GAA GTT ACA ACC GCT ACC GGC ATC GTT	96
His Gln Asn Gly Gln Val Thr Glu Val Thr Thr Ala Thr Gly Ile Val	
20 25 30	
GAT TTG GGT TCG AAA ATC GGC TTC AAA GGC CAA GAA GAC CTC GGT AAC	144
Asp Leu Gly Ser Lys Ile Gly Phe Lys Gly Gln Glu Asp Leu Gly Asn	
35 40 45	
GGC CTG AAA GCC ATT TGG CAG GTT GAG CAA AAA GCA TCT ATC GCC GGT	192
Gly Leu Lys Ala Ile Trp Gln Val Glu Gln Lys Ala Ser Ile Ala Gly	
50 55 60	
ACT GAC TCC GGT TGG GGC AAC CGC CAA TCC TTC ATC GGC TTG AAA GGC	240
Thr Asp Ser Gly Trp Gly Asn Arg Gln Ser Phe Ile Gly Leu Lys Gly	
65 70 75 80	
GGC TTC GGT AAA TTG CGC GTC GGT CGT TTG AAC AGC GTC CTG AAA GAC	288
Gly Phe Gly Lys Leu Arg Val Gly Arg Leu Asn Ser Val Leu Lys Asp	
85 90 95	
ACC GGC GAC ATC AAT CCT TGG GAT AGC AAA AGC GAC TAT TTG GGT GTA	336
Thr Gly Asp Ile Asn Pro Trp Asp Ser Lys Ser Asp Tyr Leu Gly Val	
100 105 110	
AAC AAA ATT GCC GAA CCC GAG GCA CGC CTC ATT TCC GTA CGC TAC GAT	384
Asn Lys Ile Ala Glu Pro Glu Ala Arg Leu Ile Ser Val Arg Tyr Asp	
115 120 125	
TCT CCC GAA TTT GCC GGC CTC AGC GGC AGC GTA CAA TAC GCG CTT AAC	432
Ser Pro Glu Phe Ala Gly Leu Ser Gly Ser Val Gln Tyr Ala Leu Asn	
130 135 140	
GAC AAT GCA GGC AGA CAT AAC AGC GAA TCT TAC CAC GCC GGC TTC AAC	480
Asp Asn Ala Gly Arg His Asn Ser Glu Ser Tyr His Ala Gly Phe Asn	
145 150 155 160	

FIG.4A

SUBSTITUTE SHEET (RULE 26)

5/17

TAC AAA AAC GGT GGC TTC TTC GTG CAA TAT GGC GGT GCC TAT AAA AGA Tyr Lys Asn Gly Gly Phe Phe Val Gln Tyr Gly Gly Ala Tyr Lys Arg 165 170 175	528
CAT CAT CAA GTG CAA GAG GGC TTG AAT ATT GAG AAA TAC CAG ATT CAC His His Gln Val Gln Glu Gly Leu Asn Ile Glu Lys Tyr Gln Ile His 180 185 190	576
CGT TTG GTC AGC GGT TAC GAC AAT GAT GCC CTG TAC GCT TCC GTA GCC Arg Leu Val Ser Gly Tyr Asp Asn Asp Ala Leu Tyr Ala Ser Val Ala 195 200 205	624
GTA CAG CAA CAA GAC GCG AAA CTG ACT GAT GCT TCC AAT TCG CAC AAC Val Gln Gln Gln Asp Ala Lys Leu Thr Asp Ala Ser Asn Ser His Asn 210 215 220	672
TCT CAA ACC GAA GTT GCC GCT ACC TTG GCA TAC CGC TTC GGC AAC GTA Ser Gln Thr Glu Val Ala Ala Thr Leu Ala Tyr Arg Phe Gly Asn Val 225 230 235 240	720
ACG CCC CGA GTT TCT TAC GCC CAC GGC TTC AAA GGT TTG GTT GAT GAT Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys Gly Leu Val Asp Asp 245 250 255	768
GCA GAC ATA GGC AAC GAA TAC GAC CAA GTG GTT GTC GGT GCG GAA TAC Ala Asp Ile Gly Asn Glu Tyr Asp Gln Val Val Val Gly Ala Glu Tyr 260 265 270	816
GAC TTC TCC AAA CGC ACT TCT GCC TTG GTT TCT GCC GGT TGG TTG CAA Asp Phe Ser Lys Arg Thr Ser Ala Leu Val Ser Ala Gly Trp Leu Gln 275 280 285	864
GAA GGC AAA GGC GAA AAC AAA TTC GTA GCG ACT GCC GCG GGT GTT GGT Glu Gly Lys Gly Glu Asn Lys Phe Val Ala Thr Ala Gly Gly Val Gly 290 295 300	912
CTG CGT CAC AAA TTC TAA Leu Arg His Lys Phe 305 310	930

FIG.4B

SUBSTITUTE SHEET (RULE 26)

6/17




FIG. 5

7/17




FIG. 6

8/17




FIG. 7

9/17




FIG. 8

10/17

ATG GAC GTT ACC TTG TAC GGT ACA ATT AAA GCA GGC GTA GAA GTT TCT Met Asp Val Thr Leu Tyr Gly Thr Ile Lys Ala Gly Val Glu Val Ser 1 5 10 15	48
CGC GTA AAA GAT GCT GGT ACA TAT AAA GCT CAA GGC GGA AAA TCT AAA Arg Val Lys Asp Ala Gly Thr Tyr Lys Ala Gln Gly Gly Lys Ser Lys 20 25 30	96
ACT GCA ACC CAA ATT GCC GAC TTC GGT TCT AAA ATC GGT TTC AAA GGT Thr Ala Thr Gln Ile Ala Asp Phe Gly Ser Lys Ile Gly Phe Lys Gly 35 40 45	144
CAA GAA GAC CTC GGC AAC GGC ATG AAA GCC ATT TGG CAG TTG GAA CAA Gln Glu Asp Leu Gly Asn Gly Met Lys Ala Ile Trp Gln Leu Glu Gln 50 55 60	192
AAA GCC TCC ATC GCC GGC ACT AAC AGC GGC TGG GGT AAC CGC CAG TCC Lys Ala Ser Ile Ala Gly Thr Asn Ser Gly Trp Gly Asn Arg Gln Ser 65 70 75 80	240
TTC ATC GGC TTG AAA GGC GGC TTC GGT ACC GTC CGC GCC GGT AAT CTG Phe Ile Gly Leu Lys Gly Gly Phe Gly Thr Val Arg Ala Gly Asn Leu 85 90 95	288
AAC ACC GTA TTG AAA GAC AGC GGC GAC AAC GTC AAT GCA TGG GAA TCT Asn Thr Val Leu Lys Asp Ser Gly Asp Asn Val Asn Ala Trp Glu Ser 100 105 110	336
GGT TCT AAC ACC GAA GAT GTA CTG GGA CTG GGT ACT ATC GGT CGT GTA Gly Ser Asn Thr Glu Asp Val Leu Gly Leu Gly Thr Ile Gly Arg Val 115 120 125	384
GAA AGC CGT GAA ATC TCC GTA CGC TAC GAC TCT CCC GTA TTT GCA GGC Glu Ser Arg Glu Ile Ser Val Arg Tyr Asp Ser Pro Val Phe Ala Gly 130 135 140	432
TTC AGC GGC AGC GTA CAA TAC GTT CCG CGC GAT AAT GCG AAT GAT GTG Phe Ser Gly Ser Val Gln Tyr Val Pro Arg Asp Asn Ala Asn Asp Val 145 150 155 160	480

FIG.9A

SUBSTITUTE SHEET (RULE 26)

11/17

GAT AAA TAC AAA CAT ACG AAG TCC AGC CGT GAG TCT TAC CAC GCC GGT Asp Lys Tyr Lys His Thr Lys Ser Ser Arg Glu Ser Tyr His Ala Gly 165 170 175	528
CTG AAA TAC GAA AAT GCC GGT TTC TTC GGT CAA TAC GCA GGT TCT TTT Leu Lys Tyr Glu Asn Ala Gly Phe Phe Gly Gln Tyr Ala Gly Ser Phe 180 185 190	576
GCC AAA TAT GCT GAT TTG AAC ACT GAT GCA GAA CGT GTT GCA GTA AAT Ala Lys Tyr Ala Asp Leu Asn Thr Asp Ala Glu Arg Val Ala Val Asn 195 200 205	624
ACT GCA AAT GCC CAT CCT GTT AAG GAT TAC CAA GTA CAC CGC GTA GTT Thr Ala Asn Ala His Pro Val Lys Asp Tyr Gln Val His Arg Val Val 210 215 220	672
GCC GGT TAC GAT GCC AAT GAC CTG TAC GTT TCT GTT GCC GGT CAG TAT Ala Gly Tyr Asp Ala Asn Asp Leu Tyr Val Ser Val Ala Gly Gln Tyr 225 230 235 240	720
GAA GCT GCT AAA AAC AAC GAG GTT GGT TCT ACC AAG GGT AAA AAA CAC Glu Ala Ala Lys Asn Asn Glu Val Gly Ser Thr Lys Gly Lys Lys His 245 250 255	768
GAG CAA ACT CAA GTT GCC GCT ACT GCC GCT TAC CGT TTT GGC AAC GTA Glu Gln Thr Gln Val Ala Ala Thr Ala Ala Tyr Arg Phe Gly Asn Val 260 265 270	816
ACG CCT CGC GTT TCT TAC GCC CAC GGC TTC AAA GCT AAA GTG AAT GGC Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys Ala Lys Val Asn Gly 275 280 285	864
GTG AAA GAC GCA AAT TAC CAA TAC GAC CAA GTT ATC GTT GGT GCC GAC Val Lys Asp Ala Asn Tyr Gln Tyr Asp Gln Val Ile Val Gly Ala Asp 290 295 300	912
TAC GAC TTC TCC AAA CGC ACT TCC GCT CTG GTT TCT GCC GGT TGG TTG Tyr Asp Phe Ser Lys Arg Thr Ser Ala Leu Val Ser Ala Gly Trp Leu 305 310 315 320	960

FIG.9B

SUBSTITUTE SHEET (RULE 26)

12/17

AAA CAA GGT AAA GCC GCG GGA AAA GTC GAA CAA ACT GCC AGC ATG GTT	1008
Lys Gln Gly Lys Gly Ala Gly Lys Val Glu Gln Thr Ala Ser Met Val	
325 330 335	
GGT CTG CGT CAC AAA TTC TAA	1029
Gly Leu Arg His Lys Phe	
340	

FIG.9C

13/ 17

ATG GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT TCA AGC TTG Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu 1 5 10 15	48
GTA CCG AGC TCG GAT CCA GAC GTT ACC TTG TAC GGT ACA ATT AAA GCA Val Pro Ser Ser Asp Pro Asp Val Thr Leu Tyr Gly Thr Ile Lys Ala 20 25 30	96
GGC GTA GAA GTT TCT CGC GTA AAA GAT GCT GGT ACA TAT AAA GCT CAA Gly Val Glu Val Ser Arg Val Lys Asp Ala Gly Thr Tyr Lys Ala Gln 35 40 45	144
GGC GGA AAA TCT AAA ACT GCA ACC CAA ATT GCC GAC TTC GGT TCT AAA Gly Gly Lys Ser Lys Thr Ala Thr Gln Ile Ala Asp Phe Gly Ser Lys 50 55 60	192
ATC GGT TTC AAA GGT CAA GAA GAC CTC GGC AAC GGC ATG AAA GCC ATT Ile Gly Phe Lys Gly Gln Glu Asp Leu Gly Asn Gly Met Lys Ala Ile 65 70 75 80	240
TGG CAG TTG GAA CAA AAA GCC TCC ATC GCC GGC ACT AAC AGC GGC TGG Trp Gln Leu Glu Gln Lys Ala Ser Ile Ala Gly Thr Asn Ser Gly Trp 85 90 95	288
GGT AAC CGC CAG TCC TTC ATC GGC TTG AAA GGC GGC TTC GGT ACC GTC Gly Asn Arg Gln Ser Phe Ile Gly Leu Lys Gly Gly Phe Gly Thr Val 100 105 110	336
CGC GCC GGT AAT CTG AAC ACC GTA TTG AAA GAC AGC GGC GAC AAC GTC Arg Ala Gly Asn Leu Asn Thr Val Leu Lys Asp Ser Gly Asp Asn Val 115 120 125	384
AAT GCA TGG GAA TCT GGT TCT AAC ACC GAA GAT GTA CTG GGA CTG GGT Asn Ala Trp Glu Ser Gly Ser Asn Thr Glu Asp Val Leu Gly Leu Gly 130 135 140	432
ACT ATC GGT CGT GTA GAA AGC CGT GAA ATC TCC GTA CGC TAC GAC TCT Thr Ile Gly Arg Val Glu Ser Arg Glu Ile Ser Val Arg Tyr Asp Ser 145 150 155 160	480

FIG.10A

SUBSTITUTE SHEET (RULE 26)

14/17

CCC GTA TTT GCA GGC TTC AGC GGC AGC GTA CAA TAC GTT CCG CGC GAT Pro Val Phe Ala Gly Phe Ser Gly Ser Val Gln Tyr Val Pro Arg Asp 165 170 175	528
AAT GCG AAT GAT GTG GAT AAA TAC AAA CAT ACG AAG TCC AGC CGT GAG Asn Ala Asn Asp Val Asp Lys Tyr Lys His Thr Lys Ser Ser Arg Glu 180 185 190	576
TCT TAC CAC GCC GGT CTG AAA TAC GAA AAT GCC GGT TTC TTC GGT CAA Ser Tyr His Ala Gly Leu Lys Tyr Glu Asn Ala Gly Phe Phe Gly Gln 195 200 205	624
TAC GCA GGT TCT TTT GCC AAA TAT GCT GAT TTG AAC ACT GAT GCA GAA Tyr Ala Gly Ser Phe Ala Lys Tyr Ala Asp Leu Asn Thr Asp Ala Glu 210 215 220	672
CGT GTT GCA GTA AAT ACT GCA AAT GCC CAT CCT GTT AAG GAT TAC CAA Arg Val Ala Val Asn Thr Ala Asn Ala His Pro Val Lys Asp Tyr Gln 225 230 235 240	720
GTA CAC CGC GTA GTT GCC GGT TAC GAT GCC AAT GAC CTG TAC GTT TCT Val His Arg Val Val Ala Gly Tyr Asp Ala Asn Asp Leu Tyr Val Ser 245 250 255	768
GTT GCC GGT CAG TAT GAA GCT GCT AAA AAC AAC GAG GTT GGT TCT ACC Val Ala Gly Gln Tyr Glu Ala Ala Lys Asn Asn Glu Val Gly Ser Thr 260 265 270	816
AAG GGT AAA AAA CAC GAG CAA ACT CAA GTT GCC GCT ACT GCC GCT TAC Lys Gly Lys Lys His Glu Gln Thr Gln Val Ala Ala Thr Ala Ala Tyr 275 280 285	864
CGT TTT GGC AAC GTA ACG CCT CGC GTT TCT TAC GCC CAC GGC TTC AAA Arg Phe Gly Asn Val Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys 290 295 300	912
GCT AAA GTG AAT GGC GTG AAA GAC GCA AAT TAC CAA TAC GAC CAA GTT Ala Lys Val Asn Gly Val Lys Asp Ala Asn Tyr Gln Tyr Asp Gln Val 305 310 315 320	960

FIG.10B

SUBSTITUTE SHEET (RULE 26)

15/17

ATC GTT GGT GCC GAC TAC GAC TTC TCC AAA CGC ACT TCC GCT CTG GTT	1008
Ile Val Gly Ala Asp Tyr Asp Phe Ser Lys Arg Thr Ser Ala Leu Val	
325 330 335	
TCT GCC GGT TGG TTG AAA CAA GGT AAA GCC GCG GGA AAA GTC GAA CAA	1056
Ser Ala Gly Trp Leu Lys Gln Gly Lys Gly Ala Gly Lys Val Glu Gln	
340 345 350	
ACT GCC AGC ATG GTT GGT CTG CGT CAC AAA TTC TAA	1092
Thr Ala Ser Met Val Gly Leu Arg His Lys Phe	
355 360	

FIG.10C

16/17




FIG.11A

17/17




FIG.11B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08327

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C12N 15/31, 15/53, 15/54, 15/62; C12P 21/00; A61K 39/095

US CL : 435/69.1, 69.3, 252.33, 320.1; 530/403, 416, 417; 424/92

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 69.3, 252.33, 320.1; 530/403, 416, 417; 424/92

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A, 0,467,714 (OLIFF ET AL) 22 January 1992, pages 2-37, 42-52, 55-71 and Figures 1-4.	10-12, 14, 15 and 18
X	EP, A, 0,351,604 (GOTSCHLICH ET AL) 24 January 1990, pages 2-12 and Figures 1A-1D.	10-12, 14, 15 and 18
Y	EP, A, 0,492,964 (DUNN ET AL) 01 July 1992, pages 2-13, 27 and 28 and Figures 7-18.	1-6, 10-12, 14 and 18
Y	EP, A, 0,474,313 (RODRIGUEZ ET AL) 11 March 1992, pages 3-14 and 26-28 and Figures 1-6.	1-6, 10-12, 14 and 18
Y	WO, A, 90/06696 (SEID ET AL) 28 June 1990, pages 59-77.	14, 15 and 18

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 OCTOBER 1994

Date of mailing of the international search report

08 NOV 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

WILLIAM W. MOORE

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08327

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Proceedings of the National Academy of Sciences USA, Volume 84, Number 24, issued December 1987, N.H. Carbonetti et al, "Molecular cloning and characterization of the structural gene for protein I, the major outer membrane protein of Neisseria gonorrhoeae", pages 9084-9088, see entire article.	1-6, 10-12, 14, and 18
Y	Molecular Microbiology, Volume 6, Number 23, issued December 1992, G.A. Zapata et al, "Identification of variable region differences in Neisseria meningitidis class 3 protein sequences among five group B serotypes", pages 3493-3499, see entire article.	1-6, 10-12, 14 and 18
Y	Molecular and Biochemical Parasitology, Volume 6, Number 1, issued July 1989, N. Muller et al, "Application of a recombinant Echinococcus multilocularis antigen in an enzyme-linked immunosorbent assay for immunodiagnosis of human alveolar echinococcosis", pages 151-160, see especially pages 152-156 and 158.	1-6, 10-12, 14 and 18
Y	Journal of Experimental Medicine, Volume 159, Number 2, issued February 1984, M.S. Blake et al, "Purification and Partial Characterization of the Opacity-Associated Proteins of Neisseria gonorrhoeae", pages 452-462, see especially pages, 452-459 and figures 1-5.	6, 7, 10-12, 14 and 18
Y	Infection and Immunity, Volume 57, Number 8, issued August 1989, K. Murakami et al, "Cloning and Characterization of the Structural Gene for the Class 2 Protein of Neisseria meningitidis", pages 2318-2323, see entire article.	1-6, 10-12 14 and 18
Y	Infection and Immunity, Volume 60, Number 9, issued September 1992, I.M. Feavers et al, "Molecular Analysis of the Serotyping Antigens of Neisseria meningitidis", pages 3620-3629, see especially pages 3621-3628, Table 2 and Figures 4 and 5.	1-6, 10-12, 14 and 18
Y	Biochemistry, Volume 26, Number 17, issued 25 August 1987, S.W. Lin et al, "Expression of Human Factor IX and Its Subfragments in Escherichia coli and Generation of Antibodies to the Subfragments", pages 5267-5274, see entire article.	1-6, 10-12, 14 and 18
Y	Biochemical Journal, Volume 240, Number 1, issued 15 November 1986, F.A.O. Marston, "The purification of eukaryotic polypeptides synthesized in Escherichia coli", pages 1-12, see especially pages 1-8.	1-6, 10-12, 14 and 18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08327

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Novagen, Inc., Products Catalogue, 1993, pages 1 and 36-47.	1-6, 10-12, 14 and 18
A	FEMS Microbiology Letters, Volume 33, Numbers 2/3, issued February 1986, E. Bremer et al, "Isolation and characterization of mutants deleted for the salA-ompA region of the Escherichia coli K-12 chromosome", pages 173-178.	19-24
A	Current Topics in Microbiology and Immunology, Volume 150, issued 1990, H.J. Jennings, "Capsular Polysaccharides as Vaccine Candidates", pages 97-127, see pages 105-107 and 113-120.	10-12, 14 15 and 18
A	Nature, Volume 358, Number 6389, issued 27 August 1992, S.W. Cowan et al, "Crystal structures explain functional properties of two E. coli porins", pages 727-733.	6-13
A	Bioorganic & Medicinal Chemistry Letters, Volume 1, Number 6, issued July 1991, G.J.P.H. Boons et al, "Preparation of a Well-Defined Sugar-Peptide Conjugate: A possible Approach to a Synthetic Vaccine Against Neisseria meningitidis", pages 303-308.	15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08327

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

N-GeneSeq 12, EMBL-NEW 10, UEMBL 35-78, Gen Bank-NEW 9, GenBank 78, APS,
Biosis Previews, Medline, Chemical Abstracts Search, Derwent Biotechnology Abstracts,
Current Biotechnology Abstracts, Derwent World Patent Index